<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Zoledronic acid: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Zoledronic acid: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Zoledronic acid: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11155" href="/d/html/11155.html" rel="external">see "Zoledronic acid: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="121845" href="/d/html/121845.html" rel="external">see "Zoledronic acid: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F235968"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Reclast</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868645"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Aclasta;</li>
<li>JAMP-Zoledronic Acid;</li>
<li>TARO-Zoledronic Acid;</li>
<li>Zoledronic Acid - Z;</li>
<li>Zometa</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F236015"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Bisphosphonate Derivative</li></ul></div>
<div class="block doa drugH1Div" id="F235972"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations:</b> Correct preexisting hypocalcemia and vitamin D deficiency (eg, to a 25-hydroxyvitamin D level ≥20 ng/mL [≥50 nmol/L]), when appropriate, and establish adequate calcium and vitamin D intake (diet and/or supplement) prior to infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30907953','lexi-content-ref-20061894','lexi-content-ref-Rosen.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30907953','lexi-content-ref-20061894','lexi-content-ref-Rosen.1','lexi-content-ref-Manu.1'])">Ref</a></span>). Consider delaying therapy initiation until dental health is optimized to reduce the risk of osteonecrosis of the jaw (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25234529']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25234529'])">Ref</a></span>). Acetaminophen administration after the infusion may reduce symptoms of acute-phase (influenza-like) reactions.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oncology uses:</b></p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="86d18d33-04ac-4384-a834-acfd42b29e09">Bone metastases from solid tumors</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>Bone metastases from solid tumors (Zometa): </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 4 mg once every 3 to 4 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Breast cancer or castration-resistant prostate cancer, extended dosing interval (off-label dosing): </i>
<b>IV:</b> 4 mg once every 12 weeks; dosing once every 12 weeks (versus every 4 weeks) did not result in an increased risk of skeletal events within 2 years in patients with at least 1 site of bone involvement (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28030702','lexi-content-ref-28125763']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28030702','lexi-content-ref-28125763'])">Ref</a></span>). In patients with extensive or highly symptomatic bone disease, consider 4 mg once every 4 weeks initially until bone disease is stabilized, then transition to 4 mg once every 12 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-VanPoznak.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-VanPoznak.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Duration of therapy: May continue indefinitely in patients with metastatic breast cancer, although the optimal duration of therapy has not been established in breast cancer or prostate cancer (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31990618','lexi-content-ref-29035643']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31990618','lexi-content-ref-29035643'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="27578449-59fe-43cc-95b0-983f07020be0">Breast cancer, bone loss associated with aromatase inhibitor therapy in postmenopausal patients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>Breast cancer, bone loss associated with aromatase inhibitor therapy in postmenopausal patients (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>May be used in patients at elevated risk of bone loss and/or fracture (eg, T-score −2.5 or lower, prior fragility fracture, or T-score between −1 and −2.5 at high fracture risk according to a risk assessment tool (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31532726']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31532726'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 4 mg once every 6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31532726','lexi-content-ref-21987386']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31532726','lexi-content-ref-21987386'])">Ref</a></span>) <b>or</b> 5 mg once every 12 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31532726']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31532726'])">Ref</a></span>). The optimal duration of therapy has not been established; therapy is typically continued for 3 to 5 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21987386','lexi-content-ref-18718815']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21987386','lexi-content-ref-18718815'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8097124b-5540-4f40-b050-1bbe728325fb">Breast cancer, early stage, adjuvant therapy in postmenopausal patients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>Breast cancer, early stage, adjuvant therapy in postmenopausal patients (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> May be considered in patients with a moderate to high risk of distant recurrence (≥10%) receiving adjuvant systemic therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35041467','lexi-content-ref-26681681','lexi-content-ref-VanPoznak.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35041467','lexi-content-ref-26681681','lexi-content-ref-VanPoznak.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 4 mg once every 6 months for 3 years or 4 mg once every 3 months for 2 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35041467']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35041467'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d651d917-5b3e-4644-84f8-f0afb2d722ca">Hypercalcemia of malignancy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>Hypercalcemia of malignancy (albumin-corrected serum calcium ≥12 mg/dL [≥3 mmol/L]) (Zometa):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> May also be used at the same dose for treatment of hypercalcemia due to excessive bone resorption from other causes (eg, granulomatous diseases, hyperparathyroidism, vitamin D intoxication) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26037642','lexi-content-ref-Shane.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26037642','lexi-content-ref-Shane.2020'])">Ref</a></span>). Asymptomatic or mildly symptomatic patients with chronic hypercalcemia may not require immediate treatment unless albumin-corrected serum calcium level is &gt;14 mg/dL (&gt;3.5 mmol/L) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Shane.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Shane.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 4 mg (maximum) given as a single dose. May repeat dose after 7 days if hypercalcemia persists.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a4f575b1-9ab5-4ea5-b16e-1724f4fcbc62">Multiple myeloma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>Multiple myeloma (Zometa):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note</b>: For use in conjunction with standard multiple myeloma therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29341831','lexi-content-ref-29253322']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29341831','lexi-content-ref-29253322'])">Ref</a></span>). May consider zoledronic acid for any patient with active multiple myeloma requiring treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29341831']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29341831'])">Ref</a></span>), although some reserve zoledronic acid for only those with osteolytic lesions, osteoporosis, or osteopenia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Berenson.1','lexi-content-ref-16901028']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Berenson.1','lexi-content-ref-16901028'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b> IV:</b> 4 mg once every 3 to 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29341831','lexi-content-ref-11693896','lexi-content-ref-14534891']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29341831','lexi-content-ref-11693896','lexi-content-ref-14534891'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Extended dosing interval (off-label dosing)</i>: <b>IV:</b> 4 mg once every 12 weeks may be considered in patients with stable/responsive disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29341831','lexi-content-ref-28030702']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29341831','lexi-content-ref-28030702'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Duration of therapy: Continue for up to 2 years, then reassess risks and benefits; resume therapy upon relapse (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29341831']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29341831'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bddc9a03-d14e-4739-9e13-19dee5b34eb0">Prostate cancer, bone loss associated with androgen deprivation therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>Prostate cancer, bone loss associated with androgen deprivation therapy (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>For use in patients <b>without</b> bone metastases treated long-term with androgen deprivation therapy who are at elevated risk of osteoporotic fractures (eg, T-score −2.5 or lower, prior fragility fracture, or T-score between −1 and −2.5 at high fracture risk according to a risk assessment tool) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31990618','lexi-content-ref-31532726']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31990618','lexi-content-ref-31532726'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 5 mg once every 12 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31532726','lexi-content-ref-28169118']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31532726','lexi-content-ref-28169118'])">Ref</a></span>) <b>or</b> 4 mg once every 6 to 12 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31532726','lexi-content-ref-17369566']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31532726','lexi-content-ref-17369566'])">Ref</a></span>). The optimal duration of therapy has not been established; current studies provide results for up to 36 months of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31990618','lexi-content-ref-28169118']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31990618','lexi-content-ref-28169118'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Nononcology uses:</b></p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="42d9f687-8a9c-4d6e-86a3-00829eb78170">Osteoporosis, fracture risk reduction</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>Osteoporosis, fracture risk reduction (alternative agent): Note:</b> Prior to use, evaluate and treat any potential causes of secondary osteoporosis (eg, severe vitamin D deficiency) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25182228']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25182228'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Males and postmenopausal females: </b></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Patients with high fracture risk, including those with a history of fragility fracture, </i>
<b>
<i>or</i></b>
<i> males ≥50 years of age and postmenopausal females with a T-score of −2.5 or lower or a T-score between −1 and −2.5 at high fracture risk according to a risk assessment </i>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22675062','lexi-content-ref-Finkelstein.2022','lexi-content-ref-25182228']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22675062','lexi-content-ref-Finkelstein.2022','lexi-content-ref-25182228'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Treatment: IV:</b> 5 mg once every 12 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Reclast.1','lexi-content-ref-Aclasta.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Reclast.1','lexi-content-ref-Aclasta.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Patients without high fracture risk, including those with a T-score between −1 and −2.5 and who are </i>
<b>
<i>not</i></b>
<i> at high fracture risk according to a risk assessment, but who desire pharmacologic therapy for prevention of bone loss or fracture</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Lewiecki.2022','lexi-content-ref-25182228']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Lewiecki.2022','lexi-content-ref-25182228'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Prevention: IV:</b> 5 mg once every 2 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Reclast.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Reclast.1'])">Ref</a></span>) <b>or</b> 5 mg as a single (one-time) dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aclasta.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aclasta.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Duration of therapy:</b> The optimal duration of treatment has not been established. Consider discontinuing after 3 years if bone mineral density (BMD) is stable, there have been no previous fragility fractures, and short-term fracture risk is low. If fracture risk remains high (eg, fragility fracture before or during therapy), consider extending treatment for up to 6 years or switching to alternative therapy. If discontinued, the decision to resume treatment is based on multiple factors, including decline in BMD, duration of discontinuation, and risk factors for fracture (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26350171','lexi-content-ref-30907953','lexi-content-ref-20173017']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26350171','lexi-content-ref-30907953','lexi-content-ref-20173017'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Glucocorticoid-induced:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> For use in males ≥50 years of age and postmenopausal females with low bone mineral density (T-scores between <i>−</i>1 and <i>−</i>2.5 in either group) and expected to receive systemic glucocorticoid therapy for at least 3 months at a prednisone dose of ≥7.5 mg/day (or its equivalent) <b>or</b> in any patient whose baseline risk of fracture is high and who is receiving a glucocorticoid at any dose or duration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28585373']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28585373'])">Ref</a></span>). In younger males and premenopausal females, patient selection must be individualized (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Rosen.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Rosen.2'])">Ref</a></span>). Avoid use in females who are pregnant, who plan on becoming pregnant, or who are not using effective birth control (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28585373']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28585373'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV:</b> 5 mg once every 12 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Reclast.1','lexi-content-ref-Aclasta.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Reclast.1','lexi-content-ref-Aclasta.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Duration of therapy: The optimal duration of treatment has not been established; duration should be individualized based on continuation of glucocorticoid therapy and fracture risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28585373','lexi-content-ref-35378630']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28585373','lexi-content-ref-35378630'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e26968cd-a76e-40af-abcf-7737ae0dba16">Paget disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>Paget disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Reclast.1','lexi-content-ref-Aclasta.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Reclast.1','lexi-content-ref-Aclasta.1'])">Ref</a></span>):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For symptomatic patients with active disease and select patients with asymptomatic disease at risk of future complications, or 1 to 3 months prior to planned surgery at an active pagetic site (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Charles.2022','lexi-content-ref-25406796']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Charles.2022','lexi-content-ref-25406796'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Initial: <b>IV:</b> 5 mg as a single dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Re-treatment: <b>IV:</b> A repeat 5 mg dose may be considered after 12 months in patients with biochemical relapse (eg, increase in alkaline phosphatase), radiographic progression of disease, or recurrent pain. Intensive re-treatment based on increased biochemical markers alone is not routinely recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30803025','lexi-content-ref-28176386']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30803025','lexi-content-ref-28176386'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990837"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Patients with kidney impairment may be predisposed to nephrotoxicity and symptomatic hypocalcemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18284458','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18284458','lexi-content-ref-Manu.1'])">Ref</a></span>). Prior to each dose, obtain SCr and calculate the CrCl using the Cockcroft-Gault formula with actual body weight (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<span style="text-decoration: underline">
<b>Nononcology indications:</b></span></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:6em;">CrCl ≥35 mL/minute: No dosage adjustment is necessary; use with caution in patients with CrCl &lt;80 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;35 mL/minute or evidence of acute kidney impairment: Use contraindicated due to increased risk of nephrotoxicity and lack of efficacy and safety data. Use in patients with adynamic bone disease may further suppress bone formation and theoretically increase the risk of fracture and vascular calcification (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23907861','lexi-content-ref-25940768']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23907861','lexi-content-ref-25940768'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unknown dialyzability; use contraindicated due to lack of efficacy and safety data. Use in patients with adynamic bone disease may further suppress bone formation and theoretically increase the risk of fracture and vascular calcification (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23907861','lexi-content-ref-25940768']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23907861','lexi-content-ref-25940768'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Peritoneal dialysis:</b> Unknown dialyzability; use contraindicated due to lack of efficacy and safety data. Use in patients with adynamic bone disease may further suppress bone formation and theoretically increase the risk of fracture and vascular calcification (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23907861','lexi-content-ref-25940768']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23907861','lexi-content-ref-25940768'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<span style="text-decoration: underline">
<b>Oncology indications:</b></span></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage adjustment for renal impairment <i>prior to</i> initiating zoledronic acid treatment:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Multiple myeloma and bone metastases of solid tumors:</i></b></p>
<table border="1" frame="border" rules="all" style="margin-left:8em;">
<caption style="text-align:center;">
<b>Zoledronic Acid Dose Adjustments in Altered Kidney Function<sup>a</sup></b></caption>
<colgroup><col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;text-align:center;">CrCl</p></th>
<th align="center">
<p style="text-indent:0em;">Recommended dose</p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="left" colspan="2" valign="middle">
<p style="text-indent:0em;">
<sup>a</sup>Anderson 2018; manufacturer's labeling.</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">&gt;60 mL/minute</p></td>
<td align="center">
<p style="text-indent:0em;">4 mg (no dosage adjustment necessary)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">50 to 60 mL/minute</p></td>
<td align="center">
<p style="text-indent:0em;">3.5 mg</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">40 to &lt;50 mL/minute</p></td>
<td align="center">
<p style="text-indent:0em;">3.3 mg</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">30 to &lt;40 mL/minute</p></td>
<td align="center">
<p style="text-indent:0em;">3 mg</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">&lt;30 mL/minute</p></td>
<td align="center">
<p style="text-indent:0em;">Use not recommended</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:8em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unknown dialyzability; use not recommended unless benefit outweighs risk. If necessary, some experts consider usual or reduced doses monthly in patients who are permanently on dialysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Peritoneal dialysis: </b>Use not recommended as nephrotoxicity is a concern and this patient population often has residual kidney function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18379546','lexi-content-ref-21841837']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18379546','lexi-content-ref-21841837'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Hypercalcemia of malignancy:</i></b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>SCr ≤4.5 mg/dL: </b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11208851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11208851'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>SCr &gt;4.5 mg/dL: </b> Use not recommended unless benefit outweighs risk; these patients were excluded from clinical trials (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11208851','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11208851','lexi-content-ref-Manu.1'])">Ref</a></span>); consider alternative agent when available. If necessary, some experts administer 2 to 4 mg and extend the infusion duration to 30 to 60 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Shane.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Shane.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unknown dialyzability: Use not recommended unless benefit outweighs risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>). Based on a single case report (for immobilization-induced hypercalcemia), a reduced dose of 3 mg may also be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30251313','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30251313','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Peritoneal dialysis:</b> Unknown dialyzability: Avoid use; consider alternative agent. If necessary, a reduced dose and/or extending the infusion duration to 30 to 60 minutes may be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>). Monitor closely for nephrotoxicity since peritoneal dialysis patients often have residual kidney function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18379546','lexi-content-ref-21841837']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18379546','lexi-content-ref-21841837'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage adjustment for renal toxicity </b>
<i>
<b>during</b></i>
<b> zoledronic acid treatment: </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>
<b>Hypercalcemia of malignancy:</b></i> Evidence of renal deterioration: Evaluate risk versus benefit.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>
<b>Multiple myeloma</b></i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29341831','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29341831','lexi-content-ref-Expert.DOR'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Renal deterioration without an apparent cause:</b> Withhold therapy; may resume at the prior dose when renal function returns to within 10% of baseline.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Albuminuria &gt;500 mg per 24 hours (unexplained):</b> Withhold dose until return to baseline, then reevaluate every 3 to 4 weeks; consider reinitiating with a longer infusion time of 30 minutes or longer.</p></div>
<div class="block doha drugH1Div" id="F50988060"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied); however, zoledronic acid is not metabolized hepatically. </p></div>
<div class="block dot drugH1Div" id="F55794061"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Femoral shaft fracture: Consider interrupting bisphosphonate therapy in patients who develop a femoral shaft fracture; assess for fracture in the contralateral limb.</p>
<p style="text-indent:-2em;margin-left:2em;">Musculoskeletal pain, severe: Consider discontinuing therapy in patients who experience severe symptoms.</p>
<p style="text-indent:-2em;margin-left:2em;">Ocular symptoms (conjunctivitis, uveitis, episcleritis, iritis, scleritis, or orbital inflammation): Ocular symptoms may resolve with topical steroids in some cases.</p></div>
<div class="block doe drugH1Div" id="F235973"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F53328692"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="121845" href="/d/html/121845.html" rel="external">see "Zoledronic acid: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6c603d61-6109-41f7-bcae-b135cdfc0101">Osteoporosis, primary or secondary</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteoporosis, primary or secondary:</b> Limited data available: <b>Note:</b> Acetaminophen or ibuprofen 30 minutes prior to infusion and 6 hours after is recommended to reduce acute phase reactions (eg, flu-like symptoms including low-grade fever, nausea, myalgias, and fatigue).</p>
<p style="text-indent:-2em;margin-left:4em;">Children &lt;2 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29184807']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29184807'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">First dose: IV: 0.0125 mg/kg/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance (to begin 3 months after first dose): IV: 0.025 mg/kg/dose every 3 months.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 years and Adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29184807','lexi-content-ref-17574945','lexi-content-ref-27492436']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29184807','lexi-content-ref-17574945','lexi-content-ref-27492436'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">First dose: IV: 0.0125 mg/kg/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Second dose (3 months after first dose): IV: 0.025 mg/kg/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance (to begin 6 months after first dose): IV: 0.05 mg/kg/dose every 6 months; maximum dose: 4 mg/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Dose adjustment based on lumbar spine bone mineral density (BMD) Z score: </i>Children ≥2 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">BMD Z score &gt;−2: Decrease dose to 0.025 mg/kg/dose every 6 months.</p>
<p style="text-indent:-2em;margin-left:8em;">BMD Z score &gt;0: Decrease dose to 0.025 mg/kg/dose every 12 months.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F53328693"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric dosage adjustments provided in the manufacturer's labeling; based on adult experience, dosage adjustment may be needed for mild renal impairment (ie, CrCl 35 to 60 mL/minute) and use avoided in moderate and severe impairment (ie, CrCl &lt;35 mL/minute) and acute renal insufficiency (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29184807']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29184807'])">Ref</a></span>).</p></div>
<div class="block dohp drugH1Div" id="F53328694"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); however, zoledronic acid is not metabolized hepatically.</p></div>
<div class="block arsc drugH1Div" id="F56163339"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Acute kidney injury</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute</b>
<b>kidney injury</b>, typically presenting as acute tubular necrosis, may occur with zoledronic acid. This adverse reaction may vary in severity and reversibility (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18509324','lexi-content-ref-23814519','lexi-content-ref-12787420','lexi-content-ref-18685574']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18509324','lexi-content-ref-23814519','lexi-content-ref-12787420','lexi-content-ref-18685574'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose- and time-related; typical pathology is acute tubular necrosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12787420']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12787420'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16547070']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16547070'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Repeated infusions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23814519','lexi-content-ref-16547070']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23814519','lexi-content-ref-16547070'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Short infusion times (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23814519','lexi-content-ref-16547070']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23814519','lexi-content-ref-16547070'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent nephrotoxic agents (eg, nonsteroidal anti-inflammatory drugs) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23814519']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23814519'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of treatment with other bisphosphonates (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23814519']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23814519'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23814519','lexi-content-ref-16547070']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23814519','lexi-content-ref-16547070'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Dehydration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23814519']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23814519'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23814519','lexi-content-ref-16547070']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23814519','lexi-content-ref-16547070'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Myeloma or renal cell cancer (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17136870']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17136870'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Current or prior therapy with cisplatin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17136870']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17136870'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Atrial fibrillation</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Atrial fibrillation</b> may occur with zoledronic acid (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17476007','lexi-content-ref-23690271']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17476007','lexi-content-ref-23690271'])">Ref</a></span>). This adverse reaction is debated in the literature; however, a recent meta-analysis noted that although this adverse reaction is rare, it can occur, especially in patients with risk factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25884398']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25884398'])">Ref</a></span>). The same meta-analysis reported no increased risk of stroke or cardiovascular death with the use of zoledronic acid (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25884398']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25884398'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; postulated to be a function of the alterations in intracellular ion concentrations, as well as pro-inflammatory and anti-angiogenic properties of the drug (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21090829','lexi-content-ref-20091928']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21090829','lexi-content-ref-20091928'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; typically occurs &gt;30 days postinfusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17476007','lexi-content-ref-20091928']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17476007','lexi-content-ref-20091928'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20940190']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20940190'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent cardiotoxic chemotherapy agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20940190']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20940190'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>• </b>Preexisting risk factors for atrial fibrillation (eg, older age) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20940190']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20940190'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Atypical femur fractures</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Atypical femur fractures</b> (AFF) have been reported with bisphosphonate use, including zoledronic acid. The fractures include subtrochanteric femur (bone just below the hip joint) and diaphyseal femur (long segment of the thigh bone). The benefits of therapy (when used for osteoporosis) generally outweigh the absolute risk of AFF within the first 5 years of treatment, especially in patients with high fracture risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26350171','lexi-content-ref-30907953']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26350171','lexi-content-ref-30907953'])">Ref</a></span>). The risk decreases after bisphosphonate discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32813950']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32813950'])">Ref</a></span>). AFF is estimated to occur in ~0.2% of bisphosphonate users after ≥5 years of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21343577']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21343577'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Time-related. Long-term suppression of bone turnover may be primarily responsible; however, micro-damage accumulation and alterations of collagen cross-linking have also been postulated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23712442']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23712442'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed; Most fractures have occurred in patients receiving bisphosphonates for at least 3 to 5 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31893493','lexi-content-ref-21343577']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31893493','lexi-content-ref-21343577'])">Ref</a></span>). Patients may experience prodromal pain weeks or months before the fracture occurs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20842676']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20842676'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Long-term treatment (&gt;3 to 5 years) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2010','lexi-content-ref-28396331']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2010','lexi-content-ref-28396331'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Asian race (in North America) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32813950','lexi-content-ref-23712442']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32813950','lexi-content-ref-23712442'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Femoral bowing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30169557']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30169557'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Glucocorticoid use (&gt;1 year) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30169557','lexi-content-ref-32813950']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30169557','lexi-content-ref-32813950'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypocalcemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">While transient <b>hypocalcemia</b> is expected with the use of zoledronic acid (and all bisphosphonates) secondary to its mechanism of action; cases are typically mild and asymptomatic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33631354']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33631354'])">Ref</a></span>). Hypocalcemia is typically quickly reversible with either discontinuation of zoledronic acid or use of supportive care measures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19570737']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19570737'])">Ref</a></span>). In a systematic review of clinically significant hypocalcemia in patients receiving IV bisphosphonates for bone metastases (including zoledronic acid), incidence ranged from 1% to 2% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32535678']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32535678'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: By decreasing osteoclast activity, calcium is not released into the bloodstream, causing a transient decrease in blood calcium. In patients with normally functioning parathyroid glands, calcium homeostasis is regained shortly after starting the bisphosphonate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19570737']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19570737'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; dependent on dose and indication. Hypercalcemia of malignancy: 4 to 11 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24964073']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24964073'])">Ref</a></span>); osteoporosis: 9 to 11 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17476007']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17476007'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Baseline hypocalcemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21504254','lexi-content-ref-16547070']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21504254','lexi-content-ref-16547070'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Impaired kidney function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27113952','lexi-content-ref-21504254','lexi-content-ref-19570737']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27113952','lexi-content-ref-21504254','lexi-content-ref-19570737'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Impaired parathyroid function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21504254','lexi-content-ref-19570737','lexi-content-ref-16547070']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21504254','lexi-content-ref-19570737','lexi-content-ref-16547070'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• IV bisphosphonate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21504254','lexi-content-ref-19570737']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21504254','lexi-content-ref-19570737'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Vitamin D deficiency (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21504254','lexi-content-ref-19570737','lexi-content-ref-12686715','lexi-content-ref-16547070']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21504254','lexi-content-ref-19570737','lexi-content-ref-12686715','lexi-content-ref-16547070'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hypomagnesemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16547070']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16547070'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent medications (eg, interferon-alfa, aminoglycosides, loop diuretics) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16547070']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16547070'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>• </b>Close dosing intervals (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16547070']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16547070'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Influenza-like illness/acute phase reaction</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute phase reaction-like symptoms/flu-like symptoms</b> are not life-threatening, are reversible, and typically either not observed beyond the first dose of the bisphosphonate or symptoms are less significant with subsequent exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21504254']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21504254'])">Ref</a></span>). The reaction can manifest as influenza-like symptoms, such as fatigue, arthralgia, and bone pain as well as fever and rigors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19570737']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19570737'])">Ref</a></span>). Resolution is usually observed within 2 to 3 days after symptom onset but may last up to 7 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28299378','lexi-content-ref-23184667']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28299378','lexi-content-ref-23184667'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">One study showed decreased persistence with follow-up zoledronic acid infusions in patients who experienced this adverse reaction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32303862']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32303862'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Appears to be mediated by interleukin-6, tumor necrosis factor (TNF)-alpha and other pro-inflammatory cytokines (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18045781','lexi-content-ref-19570737','lexi-content-ref-7572320','lexi-content-ref-9351880']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18045781','lexi-content-ref-19570737','lexi-content-ref-7572320','lexi-content-ref-9351880'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; typically manifests within the first 3 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21504254','lexi-content-ref-18045781','lexi-content-ref-19570737']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21504254','lexi-content-ref-18045781','lexi-content-ref-19570737'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Low pretreatment 25-OH Vitamin D levels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29498910']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29498910'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Asian race (other than Japanese) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20554708']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20554708'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Younger patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29498910','lexi-content-ref-20554708']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29498910','lexi-content-ref-20554708'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>• </b>Nitrogen-containing bisphosphonates (eg, zoledronic acid) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19570737']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19570737'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Osteonecrosis of the jaw</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteonecrosis of the jaw</b> (ONJ) was first described in the dental literature (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12966493']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12966493'])">Ref</a></span>) with the use of IV bisphosphonates, and several case reports of ONJ with IV zoledronic acid used for osteoporosis exist. The possibility of ONJ increases the risk of nonadherence dramatically (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28602783']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28602783'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose- and time-related; the exact mechanism unknown, but several hypothesized mechanisms exist, such as over-suppression of bone turnover (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16243172']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16243172'])">Ref</a></span>), mucosal toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16454811']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16454811'])">Ref</a></span>), cytokine-mediated inflammation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17614762']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17614762'])">Ref</a></span>), and infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19371816','lexi-content-ref-21504254']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19371816','lexi-content-ref-21504254'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; can be spontaneous or after insult, such as tooth extraction and/or dental implant procedures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21504254']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21504254'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>• </b> Alcohol use disorder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17663640']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17663640'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>• </b> Anemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30393090']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30393090'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>• </b>Cancer and anticancer therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17663640']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17663640'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>• </b> Corticosteroid therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17663640']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17663640'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>• </b>Dental extraction and/or dental implant procedures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17663640','lexi-content-ref-30393090']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17663640','lexi-content-ref-30393090'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>• </b> Diabetes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30393090']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30393090'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>• </b> Extended duration (&gt;3 years) of bisphosphonate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17663640']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17663640'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>• </b>High-dose, IV bisphosphonate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17663640']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17663640'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>• </b> Immunological disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30393090']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30393090'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>• </b>Oral surgery or trauma (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17663640']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17663640'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>• </b>Poor oral hygiene (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17663640']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17663640'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>• </b> Poorly fitting dental appliance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17663640']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17663640'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>• </b>Radiotherapy to head and neck (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30393090']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30393090'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>• </b>Tobacco smoking (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17663640']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17663640'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F235938"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oncology indications:</b></p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension (11%), lower extremity edema (5% to 21%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (12%), dermatitis (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Dehydration (5% to 14%), hypokalemia (12%), hypomagnesemia (11%), hypophosphatemia (13%), weight loss (16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (14% to 16%), anorexia (9% to 22%), constipation (27% to 31%), decreased appetite (13%), diarrhea (17% to 24%), nausea (29% to 46%), vomiting (14% to 32%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (12% to 14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (22% to 33%), neutropenia (12%), progression of cancer (16% to 20%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Candidiasis (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Agitation (13%), anxiety (11% to 14%), confusion (7% to 13%), depression (14%), dizziness (18%), fatigue (39%), headache (5% to 19%), hypoesthesia (12%), insomnia (15% to 16%), paresthesia (15%), rigors (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (5% to 21%), asthenia (5% to 24%), back pain (15%), limb pain (14%), myalgia (23%), ostealgia (55%), skeletal pain (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Renal insufficiency (8% to 15%; up to 40% in patients with abnormal baseline creatinine)<span class="lexi-table-link-container"> (<a aria-label="Renal Insufficiency table link" class="lexi-table-link" data-table-id="lexi-content-renal-insufficiency" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-renal-insufficiency')">table 1</a>)</span><span class="table-link" style="display:none;">Renal Insufficiency</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Renal Insufficiency" frame="border" id="lexi-content-renal-insufficiency" rules="all">
<caption style="text-align:center;">
<b>Zoledronic Acid: Adverse Reaction: Renal Insufficiency</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Zoledronic Acid)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Pamidronate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Zoledronic Acid)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Pamidronate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Multiple myeloma and breast cancer</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">246</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">246</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Normal baseline creatinine (&lt;1.4 mg/dL)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Multiple myeloma and breast cancer</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">26</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">22</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Abnormal baseline creatinine (≥1.4 mg/dL)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">40%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">20%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Prostate cancer</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Abnormal baseline creatinine (≥1.4 mg/dL)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Prostate cancer</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">82</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">68</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Normal baseline creatinine (&lt;1.4 mg/dL)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Solid tumors</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">154</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">143</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Normal baseline creatinine (&lt;1.4 mg/dL)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Solid tumors</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">11</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">20</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Abnormal baseline creatinine (≥1.4 mg/dL)</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (12% to 22%), dyspnea (22% to 27%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (32% to 44%; most common symptom of acute phase reaction)<span class="lexi-table-link-container"> (<a aria-label="Fever table link" class="lexi-table-link" data-table-id="lexi-content-fever" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-fever')">table 2</a>)</span><span class="table-link" style="display:none;">Fever</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Fever" frame="border" id="lexi-content-fever" rules="all">
<caption style="text-align:center;">
<b>Zoledronic Acid: Adverse Reaction: Fever</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Zoledronic Acid)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Pamidronate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Zoledronic Acid)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Pamidronate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">32%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">31%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">20%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IV</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bone metastases</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,031</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">556</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">455</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">44%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">33%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IV</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Hypercalcemia of malignancy</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">86</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">103</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain (5% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypermagnesemia (grade 3: 2%), hypocalcemia (5% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dyspepsia (10%), dysphagia (5% to 10%), sore throat (8%), stomatitis (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Granulocytopenia (5% to 10%), pancytopenia (5% to 10%), thrombocytopenia (5% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (nonspecific: 5% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Drowsiness (5% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (grades 3/4: ≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Upper respiratory tract infection (10%)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Nononcology indications:</b></p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension (5% to 13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypocalcemia (osteoporosis: &lt;1%; Paget disease: 3% to 21%)<span class="lexi-table-link-container"> (<a aria-label="Hypocalcemia table link" class="lexi-table-link" data-table-id="lexi-content-hypocalcemia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-hypocalcemia')">table 3</a>)</span><span class="table-link" style="display:none;">Hypocalcemia</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Hypocalcemia" frame="border" id="lexi-content-hypocalcemia" rules="all">
<caption style="text-align:center;">
<b>Zoledronic Acid: Adverse Reaction: Hypocalcemia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Zoledronic Acid)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Risedronate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Zoledronic Acid)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Risedronate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5 mg once per year</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IV</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Osteoporosis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3,862</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">21%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5 mg single dose</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IV</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Paget disease of bone</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Transient; &lt;8.4 mg/dL 9-11 days following Reclast administration</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5 mg single dose</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IV</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Paget disease of bone</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">177</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">172</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (12% to 18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Acute phase reaction-like symptoms (4% to 25%)<span class="lexi-table-link-container"> (<a aria-label="Acute Phase Reaction-like Symptoms table link" class="lexi-table-link" data-table-id="lexi-content-acute-phase-reaction-like-symptoms" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-acute-phase-reaction-like-symptoms')">table 4</a>)</span><span class="table-link" style="display:none;">Acute Phase Reaction-like Symptoms</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Acute Phase Reaction-like Symptoms" frame="border" id="lexi-content-acute-phase-reaction-like-symptoms" rules="all">
<caption style="text-align:center;">
<b>Zoledronic Acid: Adverse Reaction: Acute Phase Reaction-like Symptoms</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Zoledronic Acid)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Active Control)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Risedronate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Zoledronic Acid)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Active Control)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Risedronate)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5 mg once per year</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IV</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Osteoporosis, treatment (males)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">153</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">148</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">25%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5 mg single dose</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IV</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Paget disease of bone</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">177</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">172</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills (2% to 18%), fatigue (2% to 18%), headache (4% to 20%), pain (2% to 24%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (9% to 27%), back pain (4% to 18%), limb pain (3% to 16%), musculoskeletal pain (3% to 12%), myalgia (5% to 23%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Flu-like symptoms (≤11%)<span class="lexi-table-link-container"> (<a aria-label="Flu-like Symptoms table link" class="lexi-table-link" data-table-id="lexi-content-flu-like-symptoms" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-flu-like-symptoms')">table 5</a>)</span><span class="table-link" style="display:none;">Flu-like Symptoms</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Flu-like Symptoms" frame="border" id="lexi-content-flu-like-symptoms" rules="all">
<caption style="text-align:center;">
<b>Zoledronic Acid: Adverse Reaction: Flu-like Symptoms</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Zoledronic Acid)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Zoledronic Acid)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Active control: 2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5 mg once per year</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IV</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Osteoporosis, treatment (males)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">153</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">148</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5 mg once per year</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IV</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Osteoporosis, treatment (postmenopausal females)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3,862</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3,852</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5 mg once</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IV</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Osteoporosis, prevention</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">181</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">202</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5 mg once per year</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IV</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Osteoporosis, prevention</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">198</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">202</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5 mg once per year</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IV</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Osteoporosis, treatment (patients with recent hip fracture)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,054</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,057</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Risedronate: 6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5 mg single dose</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IV</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Paget disease of bone</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">177</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">172</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous<b>: </b>Fever (9% to 22%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrial fibrillation (≤3%)<span class="lexi-table-link-container"> (<a aria-label="Atrial Fibrillation table link" class="lexi-table-link" data-table-id="lexi-content-atrial-fibrillation" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-atrial-fibrillation')">table 6</a>)</span><span class="table-link" style="display:none;">Atrial Fibrillation</span>, chest pain (1% to 8%), palpitations (≤3%), peripheral edema (3% to 6%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Atrial Fibrillation" frame="border" id="lexi-content-atrial-fibrillation" rules="all">
<caption style="text-align:center;">
<b>Zoledronic Acid: Adverse Reaction: Atrial Fibrillation</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Zoledronic Acid)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Zoledronic Acid)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Active control: 2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5 mg once per year</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IV</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Osteoporosis, treatment (males)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">153</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">148</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5 mg once per year</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IV</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Osteoporosis, treatment (patients with recent hip fracture)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,054</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,057</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5 mg once per year</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IV</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Osteoporosis, treatment (postmenopausal females)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3,862</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3,852</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Active control: 0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IV</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Osteoporosis, glucocorticoid-induced</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">416</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">417</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Hyperhidrosis (≤3%), skin rash (2% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Dehydration (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distension (≤2%), abdominal distress (1% to 2%), abdominal pain (≤9%), anorexia (≤2%), constipation (6% to 7%), diarrhea (6%), dyspepsia (5% to 7%), vomiting (2% to 8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Change in serum protein (C-reactive protein increased; ≤5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Influenza (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection site reaction (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (6% to 9%), flank pain (≤2%), hyperthermia (≤2%), hypoesthesia (≤6%), lethargy (3% to 5%), malaise (1% to 7%), paresthesia (2%), rigors (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthritis (2% to 4%), asthenia (2% to 6%), jaw pain (2% to 4%), joint swelling (≤3%), muscle spasm (4% to 6%), neck pain (7%), ostealgia (3% to 9%), osteoarthritis (6%), shoulder pain (≤7%), stiffness (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Eye pain (≤2%), iritis (1%), uveitis (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (5% to 7%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing (all indications):</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis, pruritus, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Fanconi's syndrome (acquired) (Yoshinami 2011), hyperkalemia, hypernatremia, weight gain</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dysgeusia, xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Hematuria, proteinuria</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactic shock, anaphylaxis, angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Hyperesthesia</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Femur fracture (atypical diaphyseal and subtrochanteric) (Park-Wyllie 2011), muscle cramps, osteonecrosis (including ankle, external auditory canal, femur, hip, humerus, knee, and wrist), osteonecrosis of the jaw (Lewiecki 2011), tremor</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision, conjunctivitis, iridocyclitis, periorbital edema, periorbital swelling, scleritis (including episcleritis) (Umunakwe 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury (Edwards 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchoconstriction, bronchospasm, exacerbation of asthma, interstitial pulmonary disease</p></div>
<div class="block coi drugH1Div" id="F235951"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>US labeling:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity to zoledronic acid or any component of the formulation; hypocalcemia (Reclast only); CrCl &lt;35 mL/minute and in those with evidence of acute renal impairment (Reclast only).</p>
<p style="text-indent:0em;margin-top:2em;">
<i>Canadian labeling:</i></p>
<p style="text-indent:-2em;margin-left:4em;">All indications: Hypersensitivity to zoledronic acid or other bisphosphonates, or any component of the formulation; uncorrected hypocalcemia at the time of infusion; pregnancy, breast-feeding</p>
<p style="text-indent:-2em;margin-left:4em;">Nononcology uses: Additional contraindications: Use in patients with CrCl &lt;35 mL/minute and use in patients with evidence of acute renal impairment due to an increased risk of renal failure</p></div>
<div class="block war drugH1Div" id="F235936"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone fractures: Atypical femur fractures (AFF) have been reported in patients receiving bisphosphonates. The fractures include subtrochanteric femur (bone just below the hip joint) and diaphyseal femur (long segment of the thigh bone). Some patients experience prodromal pain weeks or months before the fracture occurs. It is unclear if bisphosphonate therapy is the cause for these fractures; AFFs have also been reported in patients not taking bisphosphonates, and in patients receiving glucocorticoids. Patients receiving long-term (&gt;3 years) IV bisphosphonate therapy may be at an increased risk (Adler 2016; NOF [Cosman 2014]); however, benefits of therapy (when used for osteoporosis) generally outweigh absolute risk of AFF within the first 3 years of treatment, especially in patients with high fracture risk (Adler 2016; ES [Eastell 2019]). Patients presenting with thigh or groin pain with a history of receiving bisphosphonates should be evaluated for femur fracture.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Rare cases of urticaria and angioedema and very rare cases of anaphylactic reactions/shock have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypocalcemia: Hypocalcemia (including severe and life-threatening cases) has been reported; patients with Paget disease may be at significant risk for hypocalcemia after treatment with zoledronic acid (because pretreatment rate of bone turnover may be elevated); severe and life-threatening hypocalcemia has also been reported with oncology-related uses. Use with caution with other medications known to cause hypocalcemia (severe hypocalcemia may develop). Use caution in patients with disturbances of calcium and mineral metabolism (eg, hypoparathyroidism, thyroid/parathyroid surgery, malabsorption syndromes, excision of small intestine). QTc prolongation, cardiac arrhythmias, and neurologic events (eg, tetany, tonic-clonic seizures, numbness) secondary to severe hypocalcemia have been reported 1 day to several months after initiation of therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Influenza-like illness/acute phase reaction: A transient acute phase reaction (eg, fever, chills, pain/myalgia, other influenza-like symptoms) may occur, typically within 3 days following the initial infusion; resolution is usually observed ~3 days after symptom onset but can take up to 14 days. The incidence of symptoms may decrease with subsequent infusions.</p>
<p style="text-indent:-2em;margin-left:4em;">• Musculoskeletal pain: Severe (and occasionally debilitating) bone, joint, and/or muscle pain have been reported during bisphosphonate treatment. The onset of pain ranged from a single day to several months. Symptoms usually resolve upon discontinuation. Some patients experienced recurrence when rechallenged with the same drug or another bisphosphonate; avoid use in patients with a history of these symptoms in association with bisphosphonate therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular effects: Conjunctivitis, uveitis, episcleritis, iritis, scleritis, and orbital inflammation have been reported with zoledronic acid.</p>
<p style="text-indent:-2em;margin-left:4em;">• Osteonecrosis of the jaw: Osteonecrosis of the jaw (ONJ), also referred to as medication-related osteonecrosis of the jaw (MRONJ), has been reported in patients receiving bisphosphonates. Known risk factors for MRONJ include invasive dental procedures (eg, tooth extraction, dental implants, bony surgery), cancer diagnosis, concomitant therapy (eg, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, ill-fitting dentures, and comorbid disorders (anemia, coagulopathy, infection, preexisting dental disease). Risk may increase with duration of bisphosphonate use and/or may be reported at a greater frequency based on tumor type (eg, advanced breast cancer or multiple myeloma). According to a position paper by the American Association of Maxillofacial Surgeons (AAOMS), MRONJ has been associated with bisphosphonates and other antiresorptive agents (denosumab), and antiangiogenic agents (eg, bevacizumab, sunitinib) used for the treatment of osteoporosis or malignancy; risk is significantly higher in cancer patients receiving antiresorptive therapy compared to patients receiving osteoporosis treatment (regardless of medication used or dosing schedule). MRONJ risk is also increased with monthly IV antiresorptive therapy compared to the minimal risk associated with oral bisphosphonate use, although risk appears to increase with oral bisphosphonates when duration of therapy exceeds 4 years. The manufacturer's labeling states that there are no data to suggest whether discontinuing bisphosphonates in patients requiring invasive dental procedures reduces the risk of ONJ. Invasive dental procedures should be avoided during therapy, if possible. The AAOMS suggests that if medically permissible, initiation of IV bisphosphonates for cancer therapy should be delayed until optimal dental health is attained (if extractions are required, antiresorptive therapy should delayed until the extraction site has mucosalized or until after adequate osseous healing). Once IV bisphosphonate therapy is initiated for oncologic disease, procedures that involve direct osseous injury and placement of dental implants be avoided. Patients developing ONJ during therapy should receive care by an oral surgeon (AAOMS [Ruggiero 2014]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Aspirin-sensitive asthma: Use with caution in patients with aspirin-sensitive asthma; may cause bronchoconstriction.</p>
<p style="text-indent:-2em;margin-left:4em;">• Breast cancer (metastatic): The American Society of Clinical Oncology (ASCO)/Cancer Care Ontario (CCO) has updated guidelines on the role of bone-modifying agents (BMAs) in metastatic breast cancer patients (ASCO/CCO [Van Poznak 2017]). The guidelines recommend initiating a BMA (denosumab, pamidronate, zoledronic acid) in patients with metastatic breast cancer to the bone. One BMA is not recommended over another (evidence supporting one BMA over another is insufficient). The analgesic effect of BMAs are modest and BMAs should not be used alone for pain management; supportive care, analgesics, adjunctive therapies, radiation therapy, surgery, and/or systemic anticancer therapy should be utilized. The ASCO/CCO guidelines are in alignment with prescribing information for dosing, renal dose adjustments, infusion times, prevention and management of osteonecrosis of the jaw, and monitoring of laboratory parameter recommendations. BMAs are not the first-line therapy for pain.</p>
<p style="text-indent:-2em;margin-left:4em;">• Multiple myeloma: The American Society of Clinical Oncology (ASCO) has updated guidelines on bone-modifying agents in multiple myeloma (ASCO [Anderson 2018]). Bisphosphonate (pamidronate or zoledronic acid) therapy should be initiated in patients with radiographic or imaging evidence of lytic bone disease. Bisphosphonates may also be considered in patients with pain secondary to osteolytic disease and as adjunct therapy in patients receiving other interventions for fractures or impending fractures. The guidelines support utilizing IV bisphosphonates in patients with multiple myeloma and osteopenia (osteoporosis) but no radiographic evidence of lytic bone disease. Bisphosphonates are not recommended in patients with solitary plasmacytoma, smoldering (asymptomatic) or indolent myeloma with osteopenia in the absence of lytic bone disease. Bisphosphonates are also not recommended in monoclonal gammopathy of undetermined significance unless osteopenia (osteoporosis) also is present. According to the guidelines, in patients with a serum creatinine &gt;3 mg/dL or CrCl &lt;30 mL/minute or extensive bone disease, an alternative bisphosphonate (pamidronate) should be used.</p>
<p style="text-indent:-2em;margin-left:4em;">• Osteoporosis in survivors of adult cancers (nonmetastatic disease): Survivors of adult cancers with nonmetastatic disease who have osteoporosis (T score of -2.5 or lower in femoral neck, total hip, or lumbar spine) or who are at increased risk of osteoporotic fractures, should be offered bone-modifying agents (utilizing the osteoporosis-indicated dose) to reduce the risk of fracture. For patients without hormonal responsive cancers, when clinically appropriate, estrogens may be administered along with other bone-modifying agents (ASCO [Shapiro 2019]). The choice of bone-modifying agent (eg, oral or IV bisphosphonates or subcutaneous denosumab) should be based on several factors (eg, patient preference, potential adverse effects, quality of life considerations, availability, adherence, cost). Adequate calcium and vitamin D intake, exercise (using a combination of exercise types), as well as lifestyle modifications (if indicated) should also be encouraged.</p>
<p style="text-indent:-2em;margin-left:4em;">• Prostate cancer: According to guidelines, denosumab is preferred over bisphosphonates in men with nonmetastatic prostate cancer receiving androgen deprivation therapy; however, bisphosphonates may be considered in situations where denosumab is unavailable or contraindicated. Bisphosphonates are not recommended to reduce the risk of first bone metastasis in men with high-risk localized prostate cancer. For preventing or delaying skeletal-related events in men with metastatic castrate-resistant prostate cancer (mCRPC), either zoledronic acid (minimally symptomatic or asymptomatic disease) or denosumab (independent of symptoms) is recommended (both at bone metastasis-indicated dosages). There is not enough evidence to make a recommendation for men with castrate-sensitive prostate cancer and bone metastases. IV bisphosphonates may be considered for palliation in men with mCRPC and bone pain. Adequate calcium and vitamin D intake, exercise (using a combination of exercise types), as well as lifestyle modifications (if indicated) are also recommended (ASCO [Saylor 2020]; CCO [Alibhai 2017]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Single and multiple infusions in patients with both normal and impaired renal function have been associated with renal deterioration, resulting in renal failure and dialysis (rare). Preexisting renal compromise, severe dehydration, and concurrent use with diuretics or other nephrotoxic drugs may increase the risk for renal impairment. Adequate hydration is required during treatment (urine output ~2 L/day); avoid overhydration, especially in patients with heart failure.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Nononcology indications: </i>Do not use single doses &gt;5 mg. Patients with underlying moderate to severe renal impairment, increased age, concurrent use of nephrotoxic or diuretic medications, or severe dehydration prior to or after zoledronic acid administration may have an increased risk of acute renal impairment or renal failure. Others with increased risk include patients with renal impairment or dehydration secondary to fever, sepsis, gastrointestinal losses, or diuretic use. If history or physical exam suggests dehydration, treatment should not be given until the patient is euvolemic. Transient increases in serum creatinine may be more pronounced in patients with impaired renal function; monitoring creatinine clearance in at-risk patients taking other renally eliminated drugs is recommended.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Oncology indications:</i> Use is not recommended in patients with serum creatinine &gt;3 mg/dL and bone metastases (limited data). In patients with cancer, do not use single doses &gt;4 mg. Risk factors for renal deterioration include preexisting renal insufficiency and repeated doses and other bisphosphonates therapy. Dehydration and the use of other nephrotoxic drugs which may contribute to renal deterioration should be identified and managed. Diuretics should not be used before correcting hypovolemia.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Because decreased renal function occurs more commonly in older adults, take special care to monitor renal function.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Duplicate therapy: Do not administer Zometa and Reclast (Aclasta [Canadian product]) to the same patient for different indications.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F53328697"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Influenza-like reactions have been reported, most commonly after the first dose occurring at 12 to 48 hours after the first infusion, and may include fever, nausea and/or vomiting, myalgia, and bone pain; treatment with standard antipyretic therapy is recommended; symptoms usually do not return with subsequent doses (Bowden 2017; Högler 2004; Munns 2007).</p>
<p style="text-indent:-2em;margin-left:2em;">May cause hypocalcemia; administration of a lower initial dose helps to reduce the risk and severity of hypocalcemia (Bowden 2017; Högler 2004; Munns 2007).</p></div>
<div class="block foc drugH1Div" id="F235946"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Concentrate, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 4 mg/5 mL (5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Concentrate, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 4 mg/5 mL (5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 4 mg/100 mL (100 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Reclast: 5 mg/100 mL (100 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 4 mg/100 mL (100 mL); 5 mg/100 mL (100 mL)</p></div>
<div class="block geq drugH1Div" id="F235932"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F235953"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Concentrate</b> (Zoledronic Acid Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 mg/5 mL (per mL): $9.00 - $192.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Reclast Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg/100 mL (per mL): $14.29</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Zoledronic Acid Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 mg/100 mL (per mL): $0.72 - $2.16</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg/100 mL (per mL): $1.20 - $4.20</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868646"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Concentrate, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zometa: 4 mg/5 mL (5 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 4 mg/5 mL (5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Aclasta: 5 mg/100 mL (100 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg/100 mL (100 mL)</p></div>
<div class="block adm drugH1Div" id="F235948"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">IV: If refrigerated, allow solution to reach room temperature before administration. Infuse over at least 15 minutes. Flush IV line with 10 mL NS flush following infusion. Infuse in a line separate from other medications. Patients must be appropriately hydrated prior to treatment. Acetaminophen after administration may reduce the incidence of acute reaction (eg, arthralgia, fever, flu-like symptoms, myalgia).</p>
<p style="text-indent:-2em;margin-left:2em;">Multiple myeloma: If treatment is withheld for unexplained albuminuria, consider increasing the infusion time to at least 30 minutes upon reinitiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29341831']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29341831'])">Ref</a></span>).</p></div>
<div class="block admp drugH1Div" id="F53328696"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;">IV: IV infusion over 30 minutes; administer via a central or peripheral line (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29184807']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29184807'])">Ref</a></span>).</p></div>
<div class="block hazard drugH1Div" id="F49132718"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 3]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block meg drugH1Div" id="F11441699"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Reclast: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2020%2F021817s028lbl.pdf%23page%3D25&amp;token=zm8AmPzIB6CYG0aEjOhjIDd2JpSpXBYUKhnxXVLBwdEh5ovLGlWIg0LIqOR74YNTGgTedr6BMDHyKJ8ZPKKObHPg%2FM8tlAD%2FJUys%2Bmfgk%2Bj4pbWT90HVgNxIiG1qRQNb&amp;TOPIC_ID=9902" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021817s028lbl.pdf#page=25</a></p></div>
<div class="block use drugH1Div" id="F235947"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Bone metastases, solid tumors:</b>
<i>Zometa</i>: Treatment of documented bone metastases from solid tumors (in conjunction with standard antineoplastic therapy). Prostate cancer should have progressed following treatment with at least one hormonal therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypercalcemia of malignancy:</b>
<i>Zometa</i>: Treatment of hypercalcemia of malignancy (albumin-corrected serum calcium ≥12 mg/dL [≥3 mmol/L]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Multiple myeloma:</b>
<i>Zometa</i>: Treatment of multiple myeloma.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteoporosis, fracture risk reduction:</b>
<i>Reclast, Aclasta [Canadian product]</i>: Treatment and prevention of osteoporosis in postmenopausal females; treatment to increase bone mass in males with osteoporosis; treatment and prevention of glucocorticoid-induced osteoporosis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Paget disease:</b>
<i>Reclast, Aclasta [Canadian product]</i>: Treatment of Paget disease of bone. <b>Note:</b> Zoledronic acid is considered the most efficacious bisphosphonate with respect to treating bone pain as well as suppressing metabolic bone activity. In patients without contraindications, Endocrine Society guidelines as well as some international guidelines recommend zoledronic acid as the treatment of choice (ES [Singer 2014]; Ralston 2019).</p></div>
<div class="block off-label drugH1Div" id="F25484313"><span class="drugH1">Use: Off-Label: Adult</span><p>Breast cancer, bone loss associated with aromatase inhibitor therapy in postmenopausal patients; Breast cancer, early stage, adjuvant therapy in postmenopausal patients; Prostate cancer, bone loss associated with androgen deprivation therapy</p></div>
<div class="block mst drugH1Div" id="F6136763"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Zometa may be confused with Jevtana, Xgeva, Xofigo, Xtandi, Zejula, Zofran, Zoladex, Zytiga</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Duplicate therapy issues: Reclast and Aclasta contain zoledronic acid, which is the same ingredient contained in Zometa; patients receiving Zometa should not be treated with Reclast or Aclasta</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13300240"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F235940"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Aminoglycosides: May enhance the hypocalcemic effect of Bisphosphonate Derivatives. Aminoglycosides may enhance the nephrotoxic effect of Bisphosphonate Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiogenesis Inhibitors (Systemic): May enhance the adverse/toxic effect of Bisphosphonate Derivatives. Specifically, the risk for osteonecrosis of the jaw may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcitonin: May enhance the hypocalcemic effect of Zoledronic Acid.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Capecitabine: Bisphosphonate Derivatives may enhance the nephrotoxic effect of Capecitabine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inhibitors of the Proton Pump (PPIs and PCABs): May diminish the therapeutic effect of Bisphosphonate Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: May enhance the hypocalcemic effect of Zoledronic Acid.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: May enhance the adverse/toxic effect of Zoledronic Acid. Specifically, the risk for ONJ or renal impairment may be increased.<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F52722866"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Evaluate pregnancy status prior to use. Females of reproductive potential should use effective contraception during and after treatment with zoledronic acid.</p>
<p style="text-indent:0em;margin-top:2em;">Underlying causes of osteoporosis should be evaluated and treated prior to considering bisphosphonate therapy in premenopausal women; effective contraception is recommended when bisphosphonate therapy is required (Pepe 2020). Bisphosphonates are incorporated into the bone matrix and gradually released over time. Because exposure prior to pregnancy may theoretically increase the risk of fetal harm, most sources recommend discontinuing bisphosphonate therapy in females of reproductive potential as early as possible prior to a planned pregnancy. Use in premenopausal females should be reserved for special circumstances when rapid bone loss is occurring; a bisphosphonate with the shortest half-life should be then used (Bhalla 2010; Pereira 2012; Stathopoulos 2011).</p>
<p style="text-indent:0em;margin-top:2em;">Oral bisphosphonates can be considered for the prevention of glucocorticoid-induced osteoporosis in premenopausal females with moderate to high risk of fracture who do not plan to become pregnant during the treatment period and are using effective birth control (or are not sexually active); intravenous therapy should be reserved for high risk patients only (ACR [Buckley 2017]).</p></div>
<div class="block pri drugH1Div" id="F235954"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">It is not known if bisphosphonates cross the placenta, but fetal exposure is expected (Djokanovic 2008; Stathopoulos 2011).</p>
<p style="text-indent:0em;margin-top:2em;">Information specific to zoledronic acid exposure during pregnancy is limited (Djokanovic 2008; Richa 2018). Bisphosphonates are incorporated into the bone matrix and gradually released over time. The amount available in the systemic circulation varies by dose and duration of therapy. Theoretically, there may be a risk of fetal harm when pregnancy follows the completion of therapy; however, available data have not shown that exposure to bisphosphonates during pregnancy significantly increases the risk of adverse fetal events (Djokanovic 2008; Green 2014; Levy 2009; Machairiotis 2019; Sokol 2019; Stathopoulos 2011). Because hypocalcemia has been described following in utero bisphosphonate exposure, exposed infants should be monitored for hypocalcemia after birth (Djokanovic 2008; Stathopoulos 2011).</p></div>
<div class="block brc drugH1Div" id="F2998081"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if zoledronic acid is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>
<div class="block dic drugH1Div" id="F235955"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Multiple myeloma or metastatic bone lesions from solid tumors: Take daily calcium supplement (500 mg) and daily multivitamin (with 400 units vitamin D).</p>
<p style="text-indent:-2em;margin-left:2em;">Osteoporosis: Ensure adequate calcium and vitamin D intake; if dietary intake is inadequate, dietary supplementation is recommended. Patients should consume:</p>
<p style="text-indent:-2em;margin-left:4em;">Calcium: 1,000 mg/day (males: 50 to 70 years of age) <b>or</b> 1,200 mg/day (females ≥51 years of age and males ≥71 years of age) (IOM 2011; NOF [Cosman 2014]).</p>
<p style="text-indent:-2em;margin-left:4em;">Vitamin D: 800 to 1,000 units/day (age ≥50 years) (NOF 2014). Recommended dietary allowance (RDA): 600 units/day (age ≤70 years) <b>or</b> 800 units/day (age ≥71 years) (IOM 2011).</p>
<p style="text-indent:-2em;margin-left:2em;">Paget disease: Take elemental calcium 1,500 mg/day (750 mg twice daily or 500 mg 3 times/day) and vitamin D 800 units/day, particularly during the first 2 weeks after administration.</p></div>
<div class="block mop drugH1Div" id="F235944"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Prior to initiation of therapy, dental exam and preventive dentistry for patients at risk for osteonecrosis, including all cancer patients. Evaluate pregnancy status prior to use (in patients who could become pregnant). Monitor for signs/symptoms of atypical femur fractures, musculoskeletal pain, and signs of ocular inflammation (may require further ophthalmologic evaluation).</p>
<p style="text-indent:-2em;margin-left:2em;">Nononcology uses: Serum creatinine prior to each dose, especially in patients with risk factors, calculate creatinine clearance before each treatment (consider interim monitoring in patients at risk for acute renal failure), evaluate fluid status and adequately hydrate patients prior to and following administration.</p>
<p style="text-indent:-2em;margin-left:4em;">Osteoporosis: Serial bone mineral density (BMD) should be evaluated at baseline and every 1 to 3 years on treatment (usually at ~2 years following initiation of therapy, then more or less frequently depending on patient-specific factors and stability of BMD) (AACE/ACE [Camacho 2020]; ES [Eastell 2019]; NOF [Cosman 2014]); evaluate BMD every 2 to 4 years during a drug holiday (ES [Eastell 2019]); in patients with combined zoledronic acid and glucocorticoid treatment, evaluate BMD at initiation of glucocorticoid therapy and after 6 to 12 months, then every 2 to 3 years if patient continues to have significant osteoporosis risk factors (ACR [Buckley 2017]); serum calcium and 25(OH)D; annual measurements of height and weight, assessment of chronic back pain; phosphorus and magnesium; may consider monitoring biochemical markers of bone turnover (eg, fasting serum CTX or urinary NTX) at baseline, 3 months, and 6 months, to assess treatment response (ES [Eastell 2019]).</p>
<p style="text-indent:-2em;margin-left:4em;">Paget disease: Serum total alkaline phosphatase at 6 to 12 weeks for initial response to treatment (when bone turnover will have shown a substantial decline) and potentially at 6 months (maximal suppression of high bone turnover); following treatment completion, monitor at ~1- to 2-year intervals (ES [Singer 2014]); monitoring more specific biochemical markers of bone turnover (eg, serum P1NP, NTX, serum beta-CTx) is generally only warranted in patients with Paget disease who have abnormal liver or biliary tract function or when early assessment of response to treatment is needed (eg, spinal compression, very active disease) (ES [Singer 2014]); serum calcium and 25(OH)D; phosphorus and magnesium; symptoms of hypocalcemia, pain (posttreatment pain may not strictly correlate with increased biochemical markers [Ralston 2019]).</p>
<p style="text-indent:-2em;margin-left:2em;">Oncology uses: Serum creatinine prior to each dose; serum electrolytes, (including calcium, phosphate, magnesium), and hemoglobin/hematocrit should be evaluated regularly throughout treatment. Monitor serum calcium to assess response and avoid overtreatment. In patients with multiple myeloma, monitor urine every 3 to 6 months for albuminuria.</p>
<p style="text-indent:-2em;margin-left:4em;">Multiple myeloma: Monitor serum creatinine (prior to each dose), serum calcium (regularly); vitamin D levels (intermittently), spot urine sample for albuminuria (every 3 to 6 months; for unexplained albuminuria &gt;500 mg/24 hours, obtain 24 urine collection to assess urinary albumin; reassess every 3 to 4 weeks with 24-hour urine collection for total protein and urine protein electrophoresis until renal function returns to baseline) (ASCO [Anderson 2018]).</p>
<p style="text-indent:-2em;margin-left:4em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p></div>
<div class="block pha drugH1Div" id="F235935"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Zoledronic acid is a bisphosphonate which inhibits bone resorption via actions on osteoclasts or on osteoclast precursors; it inhibits osteoclastic activity and skeletal calcium release induced by tumors. Decreases serum calcium and phosphorus, and increases their elimination. In osteoporosis, zoledronic acid inhibits osteoclast-mediated resorption, therefore reducing bone turnover.</p></div>
<div class="block phk drugH1Div" id="F235950"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: Binds to bone </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: 23% to 53% </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Primarily eliminated intact via the kidney; metabolism not likely</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Triphasic; Terminal: 146 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (39% ± 16% as unchanged drug) within 24 hours; feces (&lt;3%)</p></div>
<div class="block phksp drugH1Div" id="F51192022"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Mild renal impairment (CrCl 50 to 80 mL/minute) increased AUC by an average of 15%. Moderate renal impairment (CrCl 30 to 50 mL/minute) increased AUC by an average of 43%. The risk of renal deterioration appears to increase with AUC, which doubled at a CrCl of 10 mL/minute.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F235956"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Aclasta | Zoledro denk</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Acido zoledronico richet | Drolzen | Eriophos | Simpla</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Aclasta | Steozol | Zerlinda | Zoledronsaeure | Zoledronsaeure 1a pharma | Zoledronsaeure accord | Zoledronsaeure Actavis | Zoledronsaeure Fresenius kabi | Zoledronsaeure genericon | Zoledronsaeure Hospira | Zoledronsaeure sandoz | Zoledronsaeure stada | Zoledronsaeure Teva | Zometa</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Aclasta | Apo zoledronic acid | Dbl zoledronic acid | Deztron | Osteovan | Ostira | Zoledasta | Zoledronic Acid SUN</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Bonizol | Drometa | Zoledron | Zolenic | Zoltero</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Aclasta | Zoledron acid sandoz | Zoledron acid teva | Zoledronate eg | Zoledronic acid accord | Zoledronic acid eg | Zoledronic acid fresenius kabi | Zoledronic acid hospira | Zoledronic acid mylan | Zoledronic acid Sandoz | Zometa</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Aclasta | Zoledronic acid actavis | Zoledronic acid teva | Zyolix</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Acido zoledronico | Acido zoledronico blau | Aclasta | Azentex | Densis | Teoro | Zolibbs | Zometa | Zometa Livi</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Aclasta | Zoledronat accord | Zoledronat actavis onko | Zoledronat fresenius onco | Zoledronat onco labatec | Zoledronat osteo sandoz | Zoledronat Teva | Zoledronat zentiva | Zoledronsaeure onco sandoz | Zometa</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Zoledro denk | Zometa</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Acido zoledronico | Aclasta | Densis | Osteoker | Zoletero</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Aclasta | Bo lai ning | Su qi | Tianqing yi tai | Yi gu</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Acido zoledronico | Aclasta | Cenozoic | Zidolamin | Zidotor | Zidronic | Zofive | Zofrex | Zoldria | Zometa</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Apo zoledronic acid | Fayton | Osporil | Taira | Zoledronic acid accord | Zoledronic acid actavis | Zoledronic acid fresenius kabi | Zoledronic acid hospira | Zoledronic acid medac | Zoledronic acid mylan | Zoledronic acid pharmagen | Zoledronic acid ranbaxy | Zoledronic acid richter | Zoledronic acid Sandoz | Zoledronic acid teva | Zomikos</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Aclasta | Aszora | Axizoledron | Ribometa | Steozol | Zerlinda | Zoledon | Zoledro denk | Zoledron Uropharm | Zoledron Zentiva | Zoledronic acid Tillomed | Zoledronsaeure Actavis | Zoledronsaeure al | Zoledronsaeure axios | Zoledronsaeure Beta | Zoledronsaeure Fair Med | Zoledronsaeure Fresenius kabi | Zoledronsaeure hameln | Zoledronsaeure heumann | Zoledronsaeure hormosan | Zoledronsaeure Hospira | Zoledronsaeure Ibisqus | Zoledronsaeure Medac | Zoledronsaeure Mylan | Zoledronsaeure normon | Zoledronsaeure Onkovis | Zoledronsaeure phares | Zoledronsaeure resolute oncology | Zoledronsaeure stada | Zoledronsaeure Sun | Zoledronsaeure Teva | Zoledronsaeure Vipharm | Zoledronsaeure vitane | Zoledronsaure Altan | Zometa</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Acido Zoledronico Sandoz</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Acido zoledronico | Aclasta | Simpla | Zidronic</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Aclasta | Zoledronic acid accord | Zoledronic acid fresenius kabi</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Aclasta | Metadronic | Oprasta | Osteozomet | Sunnyshift | Zoledronic acid fresenius kabi</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Acido zoledronico | Acido zoledronico actavis | Acido zoledronico Aurovitas | Acido zoledronico combino pharm | Acido Zoledronico Domac | Acido zoledronico G.e.s | Acido zoledronico genfarma | Acido zoledronico hospira | Acido zoledronico kabi | Acido zoledronico kern | Acido zoledronico mylan | Acido zoledronico normon | Acido Zoledronico Sandoz | Acido zoledronico Sun | Acido Zoledronico Teva | Acido zoledronico tillomed | Zoledronic acid biomendi | Zometa</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Natzold | Zoledro denk | Zoledronic acid</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Aclasta | Tsoledronihappo hameln | Tsoledronihappo medac | Tsoledronihappo sun | Zolacitor | Zoledronic acid hospira | Zoledronic acid oresund pharma | Zoledronic acid Sandoz | Zoledronic acid Stada | Zoledronic Acid SUN</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Acide zoledronique altan | Acide zoledronique biogaran | Acide zoledronique EG | Acide zoledronique hospira | Acide zoledronique kabi | Acide zoledronique medac | Acide zoledronique mylan | Acide zoledronique sandoz | Acide zoledronique teva | Acide Zoledronique Zentiva | Aclasta | Zometa</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Zoledronic | Zoledronic acid accord | Zoledronic acid hospira | Zoledronic acid medac</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Bonevin | Zoledronic acid accord | Zoledronic acid Sandoz | Zoledronic acid zentiva | Zoledronic acid/actavis | Zoledronic acid/Generics | Zoledronic acid/hospira | Zoledronic acid/mylan | Zoledronic acid/pfizer | Zoledronic acid/zentiva | Zoxalon</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Accord zoledronic acid | Aclasta</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Zolenat | Zometa</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Osopril | Osporil | Zolacitor | Zoledronsav | Zoledronsav healthport | Zoledronsav meliopharma | Zoledronsav onkogen | Zometa | Zortila</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Sandronic | Zoffec | Zoledronic | Zoledronic acid monohydrate | Zolenic</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Aclasta | Zerlinda | Zoledronic acid accord | Zoledronic acid clonmel | Zoledronic acid hospira | Zoledronic acid Sandoz | Zometa</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Aclasta | Gemdronic | Natzold | Rokfos | Stoplos one | Vacosteo | Wellbone | Y clast | Zobone | Zolephos | Zolfrac | Zometa | Zorrent | Zyclastin | Zyrona</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Ac zoledronico zentiva | Acido zoledronico | Acido zoledronico accord | Acido zoledronico actavis | Acido Zoledronico Claris | Acido zoledronico doc generici | Acido zoledronico fresenius | Acido zoledronico hikma | Acido zoledronico hospira | Acido Zoledronico Sandoz | Acido zoledronico Sun | Acido zoledronico tillomed</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Aclasta</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Reclast | Zoledronic acid "Nichi Iko" | Zoledronic acid "towa" | Zoledronic acid nk | Zoledronic acid Sandoz | Zoledronic acid teva | Zometa</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Clastizol | Zifonate | Zoledro denk | Zoledronic acid amring | Zoledronic acid mylan</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Aclasta | Daewoong zoledron | Daihan zoledronic acid | Dongkwang zoledronic acid | Oncebone | Penmix zoledronic acid | Union zoledronic acid | Zoldron | Zoledron | Zolenic | Zolestar | Zomedron | Zometa</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Aclasta</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Aclasta | Xolarex | Zoledro denk | Zoledronat onco labatec | Zolendronic acid</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Aclasta | Zendractin | Zoledronic acid accord | Zoledronic acid Pharmidea</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Aclasta</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Aclasta | Zoledronic acid accord | Zoledronic acid medac | Zoledronic acid Pharmidea</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Acide Zoledronique Promopharm | Aclasta</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Acido zoledronico | Aclasta | Cenozoic | Eriophos | Forblas | Lezomiv | Nuzolmet | Zacpira hsp | Zolnic | Zomegoal | Zometacil</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Oledron | Zolenat</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Aclasta | Zoledro denk</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Aclasta | Zoledroninezuur | Zoledroninezuur accord | Zoledroninezuur Fresenius Kabi | Zometa</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Aclasta | Zoledo | Zoledronic acid actavis | Zoledronic acid oresund pharma | Zoledronsyre fresenius kabi | Zoledronsyre hospira | Zoledronsyre medac | Zoledronsyre sun</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Zoledronic acid mylan | Zoledronic acid viatris</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Aclasta | Oseolen | Osteozol | Ziduvin | Zoldenex | Zolenox</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Aclasta | Osteomet | Zobone | Zolechem | Zoledronic | Zolerix | Zoletalis | Zoletero | Zometa | Zoruxa</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Bonezole | Edonax | Ledronic | Macdronic | Rokfos | Zoleron | Zolita | Zometa</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Aclasta | Desinobon | Fayton | Osporil | Symdronic | Zendractin | Zerlinda | Zoledronic acid accord | Zoledronic acid actavis | Zoledronic acid claris | Zoledronic acid fresenius kabi | Zoledronic acid Sandoz | Zoledronic acid teva | Zoledronic acid zentiva | Zomikos</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Reclast | Zometa</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Acido zoledronico actavis | Acido zoledronico basi | Acido Zoledronico Combino | Acido Zoledronico dna pharma | Acido zoledronico fresenius kabi | Acido zoledronico generis | Acido zoledronico hikma | Acido zoledronico hospira | Acido zoledronico medac | Acido zoledronico normon | Acido Zoledronico Sandoz | Acido Zoledronico Teva | Acido zoledronico zentiva | Zometa</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Acido zoledronico bioteng | Acido zoledronico libra | Acido zoledronico nortelab | Aclasta | Zometa</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Aclasta | Xolarex | Zometa</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Acid zoledronic accord | Acid zoledronic actavis | Acid zoledronic fresenius kabi | Acid zoledronic hospira | Acid zoledronic sandoz | Acid zoledronic terapia | Acid zoledronic teva | Acid zoledronic zentiva | Aclasta | Desinobon | Fayton | Osporil | Zerlinda | Zyolix</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Aclasta | Metastazol | Osteostatix | Rezoclastin | Rezoklastin fs | Targezol | Veroklast | Zoledronat Teva | Zolerix | Zoltero | Zometa</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Zidronic | Zolacin | Zoledronic acid fresenius kabi | Zoledronic acid spc | Zolenat</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Aclasta | Zerlinda | Zoledronic acid accord | Zoledronic acid actavis | Zoledronic acid fresenius kabi | Zoledronic acid hospira | Zoledronic acid mylan | Zoledronic acid oresund pharma | Zoledronic acid teva | Zoledronsyra abacus medicine | Zoledronsyra hameln | Zoledronsyra stada | Zoledronsyra sun | Zolendrosyra medac | Zolestad | Zometa</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Zoledronic acid fresenius kabi | Zova</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Aclasta | Zoledronic acid mylan | Zoledronska kislina Accord | Zometa</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Aclasta | Fayton | Kyselina zoledronova medac | Osporil | Zoledronat stada | Zoledronic acid actavis | Zoledronic acid fresenius kabi | Zoledronic acid pharmacenter | Zoledronic acid pharmagen | Zoledronic acid ranbaxy | Zolemed | Zometa | Zomikos</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Leuzotev | Zinvel | Zolennic</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Aclasta | Medistar | Zometa</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Aclabon | Aclasta | Bondrex | Bonedro | Bonzolen | Laniczol | Metarzu | Ossi | Ostezolen | Ronidro | Ronix | Vertebzol | Xendro | Zodinasil | Zoldria | Zoledrin | Zolenat | Zolka | Zolonik | Zoloporoz | Zoltasta | Zoltonar | Zomebon | Zomtu</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Bonecare | Cakeep</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Acidum zoledronic | Aclasta | Blaztere h | Destron | Metakos | Monteron | Zolacid | Zoledro denk | Zoledronicacid pharmex | Zolemeda | Zolendrovista | Zoleum | Zolevista | Zolta | Zoltero</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Zoledro denk | Zometa</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Acido zoledronico | Aclasta | Densis | Osteogen | Zodronic</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Aclasta | Simpla</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Digafil | Ledrobon | Zogenex | Zopylas</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Austell zoledronic | Dronamyl | Eurodron | Zoclasta | Zolapor | Zomabon | Zomedron | Zosteopor | Zostepor</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Zoledronic acid mylan | Zometa</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aclasta.1">
<a name="Aclasta.1"></a>Aclasta (zoledronic acid) [product monograph]. Boucherville, Quebec, Canada: Sandoz Canada Inc; December 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26350171">
<a name="26350171"></a>Adler RA, El-Hajj Fuleihan G, Bauer DC, et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research. <i>J Bone Miner Res</i>. 2016;31(1):16-35. doi:10.1002/jbmr.2708<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/26350171/pubmed" id="26350171" target="_blank">26350171</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28169118">
<a name="28169118"></a>Alibhai SMH, Zukotynski K, Walker-Dilks C, et al; Cancer Care Ontario Genitourinary Cancer Disease Site Group. Bone health and bone-targeted therapies for prostate cancer: a programme in evidence-based care - Cancer Care Ontario clinical practice guideline. <i>Clin Oncol (R Coll Radiol)</i>. 2017;29(6):348-355. doi:10.1016/j.clon.2017.01.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/28169118/pubmed" id="28169118" target="_blank">28169118</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19371816">
<a name="19371816"></a>Allen MR, Burr DB. The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. <i>J Oral Maxillofac Surg</i>. 2009;67(5 suppl):61-70. doi:10.1016/j.joms.2009.01.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/19371816/pubmed" id="19371816" target="_blank">19371816</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16873332">
<a name="16873332"></a>American Dental Association Council on Scientific Affairs. Dental Management of Patients Receiving Oral Bisphosphonate Therapy. <i>JADA.</i> 2006;137(8):1144-1150. http://jada.ada.org/article/S0002-8177(14)64960-6/pdf.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/16873332/pubmed" id="16873332" target="_blank">16873332</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29341831">
<a name="29341831"></a>Anderson K, Ismaila N, Flynn PJ, et al. Role of bone-modifying agents in multiple myeloma: American Society of Clinical Oncology clinical practice guideline update. <i>J Clin Oncol</i>. 2018;36(8):812-818. doi:10.1200/JCO.2017.76.6402<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/29341831/pubmed" id="29341831" target="_blank">29341831</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Berenson.1">
<a name="Berenson.1"></a>Berenson JR. Multiple myeloma: The use of osteoclast inhibitors. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 20, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21465735">
<a name="21465735"></a>Berenson JR, Boccia R, Lopez T, et al. Results of a Multicenter Open-Label Randomized Trial Evaluating Infusion Duration of Zoledronic Acid in Multiple Myeloma Patients (the ZMAX Trial). <i>J Support Oncol.</i> 2011;9(1):32-40.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/21465735/pubmed" id="21465735" target="_blank">21465735</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20534366">
<a name="20534366"></a>Bhalla AK. Management of Osteoporosis in a Pre-menopausal Woman. <i>Best Pract Res Clin Rheumatol. </i>2010;24(3):313-327.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/20534366/pubmed" id="20534366" target="_blank">20534366</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30169557">
<a name="30169557"></a>Black DM, Abrahamsen B, Bouxsein ML, Einhorn T, Napoli N. Atypical femur fractures: Review of epidemiology, relationship to bisphosphonates, prevention, and clinical management. <i>Endocr Rev</i>. 2019;40(2):333-368. doi:10.1210/er.2018-00001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/30169557/pubmed" id="30169557" target="_blank">30169557</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17476007">
<a name="17476007"></a>Black DM, Delmas PD, Eastell R, et al. Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis. <i>New Engl J Med.</i> 2007;356(18):1809-1822.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/17476007/pubmed" id="17476007" target="_blank">17476007</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32813950">
<a name="32813950"></a>Black DM, Geiger EJ, Eastell R, et al. Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates. <i>N Engl J Med</i>. 2020;383(8):743-753. doi:10.1056/NEJMoa1916525<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/32813950/pubmed" id="32813950" target="_blank">32813950</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9362440">
<a name="9362440"></a>Body JJ. Clinical Research Update: Zoledronate. <i>Cancer.</i> 1997;80(suppl):1699-1701.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/9362440/pubmed" id="9362440" target="_blank">9362440</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18509324">
<a name="18509324"></a>Boonen S, Sellmeyer DE, Lippuner K, et al. Renal Safety of Annual Zoledronic Acid Infusions in Osteoporotic Postmenopausal Women. <i>Kidney Int.</i> 2008;74(5):641-648.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/18509324/pubmed" id="18509324" target="_blank">18509324</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29184807">
<a name="29184807"></a>Bowden SA, Mahan JD. Zoledronic acid in pediatric metabolic bone disorders. <i>Transl Pediatr</i>. 2017;6(4):256-268. doi:10.21037/tp.2017.09.10<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/29184807/pubmed" id="29184807" target="_blank">29184807</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21987386">
<a name="21987386"></a>Brufsky AM, Harker WG, Beck JT, et al. Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. <i>Cancer</i>. 2012;118(5):1192-1201. doi:10.1002/cncr.26313<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/21987386/pubmed" id="21987386" target="_blank">21987386</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17159193">
<a name="17159193"></a>Brufsky A, Harker WG, Beck JT, et al. Zoledronic Acid Inhibits Adjuvant Letrozole-Induced Bone Loss in Postmenopausal Women With Early Breast Cancer. <i>J Clin Oncol.</i> 2007;25(7):829-836.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/17159193/pubmed" id="17159193" target="_blank">17159193</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28585373">
<a name="28585373"></a>Buckley L, Guyatt G, Fink HA, et al. 2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. <i>Arthritis Rheumatol</i>. 2017;69(8):1521-1537. doi:10.1002/art.40137<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/28585373/pubmed" id="28585373" target="_blank">28585373</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32427503">
<a name="32427503"></a>Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. <i>Endocr Pract</i>. 2020;26(suppl 1):s1-s46. doi:10.4158/GL-2020-0524SUPPL<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/32427503/pubmed" id="32427503" target="_blank">32427503</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Charles.2022">
<a name="Charles.2022"></a>Charles JF. Treatment of Paget disease of bone. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 20, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18284458">
<a name="18284458"></a>Chennuru S, Koduri J, Baumann MA. Risk factors for symptomatic hypocalcaemia complicating treatment with zoledronic acid. <i>Intern Med J</i>. 2008;38(8):635-637. doi:10.1111/j.1445-5994.2007.01580.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/18284458/pubmed" id="18284458" target="_blank">18284458</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21995387">
<a name="21995387"></a>Coleman RE, Marshall H, Cameron D, et al. Breast-Cancer Adjuvant Therapy With Zoledronic Acid. <i>N Engl J Med.</i> 2011;365(15):1396-1405.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/21995387/pubmed" id="21995387" target="_blank">21995387</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11346860">
<a name="11346860"></a>Coleman RE, Seaman JJ. The Role of Zoledronic Acid in Cancer: Clinical Studies in the Treatment and Prevention of Bone Metastases. <i>Semin Oncol.</i> 2001;28(2)(suppl 6):11-16.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/11346860/pubmed" id="11346860" target="_blank">11346860</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25182228">
<a name="25182228"></a>Cosman F, de Beur SJ, LeBoff MS, et al; National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. <i>Osteoporos Int</i>. 2014;25(10):2359-2381. doi:10.1007/s00198-014-2794-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/25182228/pubmed" id="25182228" target="_blank">25182228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29498910">
<a name="29498910"></a>Crotti C, Watts NB, De Santis M, et al. Acute phase reactions after zoledronic acid infusion: protective role of 25-hydroxyvitamin D and previous oral bisphosphonate therapy. <i>Endocr Pract</i>. 2018;24(5):405-410. doi:10.4158/EP161638.OR<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/29498910/pubmed" id="29498910" target="_blank">29498910</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27808435">
<a name="27808435"></a>Cundy T, Maslowski K, Grey A, Reid IR. Durability of response to zoledronate treatment and competing mortality in Paget's disease of bone. <i>J Bone Miner Res</i>. 2017;32(4):753-756. doi:10.1002/jbmr.3029.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/27808435/pubmed" id="27808435" target="_blank">27808435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19175968">
<a name="19175968"></a>Djokanovic N, Klieger-Grossmann C, Koren G. Does Treatment With Bisphosphonates Endanger the Human Pregnancy? <i>J Obstet Gynaecol Can.</i> 2008;30(12):1146-1148.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/19175968/pubmed" id="19175968" target="_blank">19175968</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16000365">
<a name="16000365"></a>Durie BG, Katz M, Crowley J. Osteonecrosis of the Jaw and Bisphosphonates. <i>N Engl J Med.</i> 2005;353(1):99-102.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/16000365/pubmed" id="16000365" target="_blank">16000365</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30907953">
<a name="30907953"></a>Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2019;104(5):1595-1622. doi:10.1210/jc.2019-00221<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/30907953/pubmed" id="30907953" target="_blank">30907953</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26896384">
<a name="26896384"></a>Edwards BJ, Sun M, West DP, et al. Incidence of atypical femur fractures in cancer patients: The MD Anderson Cancer Center experience. <i>J Bone Miner Res</i>. 2016;31(8):1569-1576. doi:10.1002/jbmr.2818<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/26896384/pubmed" id="26896384" target="_blank">26896384</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23814519">
<a name="23814519"></a>Edwards BJ, Usmani S, Raisch DW, et al. Acute kidney injury and bisphosphonate use in cancer: a report from the research on adverse drug events and reports (RADAR) project. <i>J Oncol Pract</i>. 2013;9(2):101-106. doi:10.1200/JOP.2011.000486<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/23814519/pubmed" id="23814519" target="_blank">23814519</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20444845">
<a name="20444845"></a>Eidtmann H, de Boer R, Bundred N, et al. Efficacy of Zoledronic Acid in Postmenopausal Women With Early Breast Cancer Receiving Adjuvant Letrozole: 36-Month Results of the ZO-FAST Study. <i>Ann Oncol.</i> 2010;21(11):2188-2194.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/20444845/pubmed" id="20444845" target="_blank">20444845</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35041467">
<a name="35041467"></a>Eisen A, Somerfield MR, Accordino MK, et al. Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: ASCO-OH (CCO) guideline update. <i>J Clin Oncol</i>. 2022;40(7):787-800. doi:10.1200/JCO.21.02647<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/35041467/pubmed" id="35041467" target="_blank">35041467</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.2010">
<a name="FDA.2010"></a>FDA Drug Safety Communication: Safety update for osteoporosis drugs, bisphosphonates, and atypical fractures. Safety Announcement. 2010 October 13.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Finkelstein.2022">
<a name="Finkelstein.2022"></a>Finkelstein JS, Yu EW. Treatment of osteoporosis in men. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 20, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21531932">
<a name="21531932"></a>Francini F, Pascucci A, Francini E, et al. Osteonecrosis of the Jaw in Patients With Cancer Who Received Zoledronic Acid and Bevacizumab. <i>J Am Dent Assoc.</i> 2011;142(5):506-513.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/21531932/pubmed" id="21531932" target="_blank">21531932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17614762">
<a name="17614762"></a>Galluzzo S, Santini D, Vincenzi B, Caccamo N, Meraviglia F, Salerno A, Dieli F, Tonini G. Immunomodulating role of bisphosphonates on human gamma delta T cells: an intriguing and promising aspect of their antitumour activity. <i>Expert Opin Ther Targets</i>. 2007;11(7):941-954. doi:10.1517/14728222.11.7.941<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/17614762/pubmed" id="17614762" target="_blank">17614762</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18718815">
<a name="18718815"></a>Gnant M, Mlineritsch B, Luschin-Ebengreuth G, et al; Austrian Breast and Colorectal Cancer Study Group (ABCSG). Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. <i>Lancet Oncol</i>. 2008;9(9):840-849. doi:10.1016/S1470-2045(08)70204-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/18718815/pubmed" id="18718815" target="_blank">18718815</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19213681">
<a name="19213681"></a>Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine Therapy Plus Zoledronic Acid in Premenopausal Breast Cancer. <i>N Engl J Med.</i> 2009;360(7):679-691.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/19213681/pubmed" id="19213681" target="_blank">19213681</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31693129">
<a name="31693129"></a>Gralow JR, Barlow WE, Paterson AHG, et al. Phase III randomized trial of bisphosphonates as adjuvant therapy in breast cancer: S0307. <i>J Natl Cancer Inst</i>. 2020;112(7):698-707. doi:10.1093/jnci/djz215<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/31693129/pubmed" id="31693129" target="_blank">31693129</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21037195">
<a name="21037195"></a>Grbic JT, Black DM, Lyles KW, et al. The Incidence of Osteonecrosis of the Jaw in Patients Receiving 5 Milligrams of Zoledronic Acid: Data From the Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly Clinical Trials Program. <i>J Am Dent Assoc.</i> 2010;141(11):1365-1370.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/21037195/pubmed" id="21037195" target="_blank">21037195</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25404594">
<a name="25404594"></a>Green SB, Pappas AL. Effects of maternal bisphosphonate use on fetal and neonatal outcomes. <i>Am J Health Syst Pharm</i>. 2014;71(23):2029-2036.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/25404594/pubmed" id="25404594" target="_blank">25404594</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35378630">
<a name="35378630"></a>Gregson CL, Armstrong DJ, Bowden J, et al. UK clinical guideline for the prevention and treatment of osteoporosis. <i>Arch Osteoporos.</i> 2022;17(1):58. doi:10.1007/s11657-022-01061-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/35378630/pubmed" id="35378630" target="_blank">35378630</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12631097">
<a name="12631097"></a>Haas M, Leko-Mohr Z, Roschger P, et al. Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation. <i>Kidney Int</i>. 2003;63(3):1130-1136.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/12631097/pubmed" id="12631097" target="_blank">12631097</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21415233">
<a name="21415233"></a>Hadji P, Aapro MS, Body JJ, et al. Management of Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Breast Cancer: Practical Guidance for Prevention and Treatment. <i>Ann Oncol.</i> 2011;22(12):2546-2555.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/21415233/pubmed" id="21415233" target="_blank">21415233</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26681681">
<a name="26681681"></a>Hadji P, Coleman RE, Wilson C, et al. Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European panel. <i>Ann Oncol</i>. 2016;27(3):379-390. doi:10.1093/annonc/mdv617<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/26681681/pubmed" id="26681681" target="_blank">26681681</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28602783">
<a name="28602783"></a>Hall SF, Edmonds SW, Lou Y, et al. Patient-reported reasons for nonadherence to recommended osteoporosis pharmacotherapy. <i>J Am Pharm Assoc</i> (2003). 2017;57(4):503-509. doi:10.1016/j.japh.2017.05.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/28602783/pubmed" id="28602783" target="_blank">28602783</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16454811">
<a name="16454811"></a>Hansen T, Kunkel M, Weber A, James Kirkpatrick C. Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis. <i>J Oral Pathol Med</i>. 2006;35(3):155-160. doi:10.1111/j.1600-0714.2006.00391.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/16454811/pubmed" id="16454811" target="_blank">16454811</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32058842">
<a name="32058842"></a>Hassett MJ, Somerfield MR, Baker ER, et al. Management of male breast cancer: ASCO guideline. <i>J Clin Oncol</i>. 2020;38(16):1849-1863. doi:10.1200/JCO.19.03120<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/32058842/pubmed" id="32058842" target="_blank">32058842</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22041409">
<a name="22041409"></a>Hellstein JW, Adler RA, Edwards B, et al. Managing the Care of Patients Receiving Antiresorptive Therapy for Prevention and Treatment of Osteoporosis: Executive Summary of Recommendations From the American Dental Association Council on Scientific Affairs. <i>J Am Dent Assoc.</i> 2011;142(11):1243-1251.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/22041409/pubmed" id="22041409" target="_blank">22041409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hellstein.2013">
<a name="Hellstein.2013"></a>Hellstein JW, Adler RA, Edwards B, et al, "Managing the Care of Patients Receiving Antiresorptive Therapy for Prevention and Treatment of Osteoporosis: Recommendations From the American Dental Association Council on Scientific Affairs," 2011, Available at http://www.ada.org/sections/professionalResources/pdfs/topics_ARONJ_report.pdf. Accessed February 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20022990">
<a name="20022990"></a>Hershman DL, McMahon DJ, Crew KD, et al. Prevention of Bone Loss By Zoledronic Acid in Premenopausal Women Undergoing Adjuvant Chemotherapy Persist Up to One Year Following Discontinuing Treatment. <i>J Clin Endocrinol Metab.</i> 2010;95(2):559-566.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/20022990/pubmed" id="20022990" target="_blank">20022990</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12963702">
<a name="12963702"></a>Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 Update on the Role of Bisphosphonates and Bone Health Issues in Women With Breast Cancer. <i>J Clin Oncol. </i>2003;21(21):4042-4057.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/12963702/pubmed" id="12963702" target="_blank">12963702</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28030702">
<a name="28030702"></a>Himelstein AL, Foster JC, Khatcheressian JL, et al. Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial. <i>JAMA</i>. 2017;317(1):48-58. doi:10.1001/jama.2016.19425<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/28030702/pubmed" id="28030702" target="_blank">28030702</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15520785">
<a name="15520785"></a>Högler W, Yap F, Little D, Ambler G, McQuade M, Cowell CT. Short-term safety assessment in the use of intravenous zoledronic acid in children. <i>J Pediatr</i>. 2004;145(5):701-704.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/15520785/pubmed" id="15520785" target="_blank">15520785</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28125763">
<a name="28125763"></a>Hortobagyi GN, Van Poznak C, Harker WG, et al. Continued treatment effect of zoledronic acid dosing every 12 vs 4 weeks in women with breast cancer metastatic to bone: the OPTIMIZE-2 randomized clinical trial. <i>JAMA Oncol</i>. 2017;3(7):906-912. doi:10.1001/jamaoncol.2016.6316<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/28125763/pubmed" id="28125763" target="_blank">28125763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21090829">
<a name="21090829"></a>Howard PA, Barnes BJ, Vacek JL, Chen W, Lai SM. Impact of bisphosphonates on the risk of atrial fibrillation. <i>Am J Cardiovasc Drugs</i>. 2010;10(6):359-367. doi:10.2165/11584720-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/21090829/pubmed" id="21090829" target="_blank">21090829</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-IOM.1">
<a name="IOM.1"></a>IOM (Institute of Medicine), <i>Dietary Reference Intakes for Calcium and Vitamin D,</i> Washington, DC: The National Academies Press, 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33631354">
<a name="33631354"></a>Jara MA, Varghese J, Hu MI. Adverse events associated with bone-directed therapies in patients with cancer. <i>Bone</i>. 2021 Feb 22:115901. doi:10.1016/j.bone.2021.115901<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/33631354/pubmed" id="33631354" target="_blank">33631354</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32642421">
<a name="32642421"></a>Kaku T, Oh Y, Sato S, et al. Incidence of atypical femoral fractures in the treatment of bone metastasis: An alert report. <i>J Bone Oncol</i>. 2020;23:100301. doi:10.1016/j.jbo.2020.100301<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/32642421/pubmed" id="32642421" target="_blank">32642421</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27113952">
<a name="27113952"></a>Kaur U, Chakrabarti SS, Gambhir IS. Zoledronate induced hypocalcemia and hypophosphatemia in osteoporosis: A cause of concern. <i>Curr Drug Saf</i>. 2016;11(3):267-269. doi:10.2174/1574886311666160426141647<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/27113952/pubmed" id="27113952" target="_blank">27113952</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28396331">
<a name="28396331"></a>Khan AA, Kaiser S. Atypical femoral fracture. <i>CMAJ</i>. 2017;189(14):E542. doi:10.1503/cmaj.160450<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/28396331/pubmed" id="28396331" target="_blank">28396331</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25414052">
<a name="25414052"></a>Khan AA, Morrison A, Hanley DA, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. <i>J Bone Miner Res.</i> 2015; 30(1):3-23.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/25414052/pubmed" id="25414052" target="_blank">25414052</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17663640">
<a name="17663640"></a>Khosla S, Burr D, Cauley J, et al; American Society for Bone and Mineral Research. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. <i>J Bone Miner Res</i>. 2007;22(10):1479-1491. doi:10.1359/jbmr.0707onj<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/17663640/pubmed" id="17663640" target="_blank">17663640</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25884398">
<a name="25884398"></a>Kim DH, Rogers JR, Fulchino LA, Kim CA, Solomon DH, Kim SC. Bisphosphonates and risk of cardiovascular events: a meta-analysis. <i>PLoS One</i>. 2015;10(4):e0122646. doi:10.1371/journal.pone.0122646<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/25884398/pubmed" id="25884398" target="_blank">25884398</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24964073">
<a name="24964073"></a>Kreutle V, Blum C, Meier C, et al. Bisphosphonate induced hypocalcaemia - report of six cases and review of the literature. <i>Swiss Med Wkly</i>. 2014;144:w13979. doi:10.4414/smw.2014.13979<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/24964073/pubmed" id="24964073" target="_blank">24964073</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17515569">
<a name="17515569"></a>Kyle RA, Yee GC, Somerfield MR, et al. American Society of Clinical Oncology 2007 Clinical Practice Guideline Update on the Role of Bisphosphonates in Multiple Myeloma. <i>J Clin Oncol.</i> 2007;25(17):2464-2472.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/17515569/pubmed" id="17515569" target="_blank">17515569</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16901028">
<a name="16901028"></a>Lacy MQ, Dispenzieri A, Gertz MA, et al. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. <i>Mayo Clin Proc</i>. 2006;81(8):1047-1053. doi:10.4065/81.8.1047<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/16901028/pubmed" id="16901028" target="_blank">16901028</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28394826">
<a name="28394826"></a>Langdahl BL. Osteoporosis in premenopausal women. <i>Curr Opin Rheumatol</i>. 2017;29(4):410-415. doi:10.1097/BOR.0000000000000400.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/28394826/pubmed" id="28394826" target="_blank">28394826</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19059370">
<a name="19059370"></a>Levy S, Fayez I, Taguchi N, et al. Pregnancy Outcome Following <i>in utero</i> Exposure to Bisphosphonates. <i>Bone.</i> 2009;44(3):428-430.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/19059370/pubmed" id="19059370" target="_blank">19059370</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lewiecki.2022">
<a name="Lewiecki.2022"></a>Lewiecki EM. Prevention of osteoporosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 20, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21504254">
<a name="21504254"></a>Lewiecki EM. Safety of long-term bisphosphonate therapy for the management of osteoporosis. <i>Drugs</i>. 2011;71(6):791-814. doi:10.2165/11585470-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/21504254/pubmed" id="21504254" target="_blank">21504254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17878149">
<a name="17878149"></a>Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic Acid and Clinical Fractures and Mortality After Hip Fracture. <i>N Engl J Med.</i> 2005;357(18):1799-1809.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/17878149/pubmed" id="17878149" target="_blank">17878149</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31539355">
<a name="31539355"></a>Machairiotis N, Ntali G, Kouroutou P, Michala L. Clinical evidence of the effect of bisphosphonates on pregnancy and the infant. <i>Horm Mol Biol Clin Investig</i>. Published online September 20, 2019. doi:10.1515/hmbci-2019-0021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/31539355/pubmed" id="31539355" target="_blank">31539355</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16003838">
<a name="16003838"></a>Maerevoet M, Martin C, and Duck L. Osteonecrosis of the Jaw and Bisphosphonates. <i>N Engl J Med.</i> 2005;353(1):99-102.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/16003838/pubmed" id="16003838" target="_blank">16003838</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11208851">
<a name="11208851"></a>Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. <i>J Clin Oncol</i>. 2001;19(2):558-567. doi:10.1200/JCO.2001.19.2.558<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/11208851/pubmed" id="11208851" target="_blank">11208851</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31893493">
<a name="31893493"></a>Marchand D, Loshak H. Duration of bisphosphonate treatment for patients with osteoporosis: A review of clinical effectiveness and guidelines [internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Oct 4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/31893493/pubmed" id="31893493" target="_blank">31893493</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12787420">
<a name="12787420"></a>Markowitz GS, Fine PL, Stack JI, et al. Toxic acute tubular necrosis following treatment with zoledronate (<i>Zometa</i>). <i>Kidney Int</i>. 2003;64(1):281-289. doi:10.1046/j.1523-1755.2003.00071.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/12787420/pubmed" id="12787420" target="_blank">12787420</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18379546">
<a name="18379546"></a>Marrón B, Remón C, Pérez-Fontán M, Quirós P, Ortíz A. Benefits of preserving residual renal function in peritoneal dialysis. <i>Kidney Int Suppl</i>. 2008;(108):S42-S51. doi:10.1038/sj.ki.5002600<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/18379546/pubmed" id="18379546" target="_blank">18379546</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12966493">
<a name="12966493"></a>Marx RE. Pamidronate (<i>Aredia</i>) and zoledronate (<i>Zometa</i>) induced avascular necrosis of the jaws: a growing epidemic. <i>J Oral Maxillofac Surg</i>. 2003;61(9):1115-1117. doi:10.1016/s0278-2391(03)00720-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/12966493/pubmed" id="12966493" target="_blank">12966493</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16243172">
<a name="16243172"></a>Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. <i>J Oral Maxillofac Surg</i>. 2005;63(11):1567-1575. doi:10.1016/j.joms.2005.07.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/16243172/pubmed" id="16243172" target="_blank">16243172</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20168099">
<a name="20168099"></a>McClung M, Miller P, Recknor C, et al. Zoledronic Acid for the Prevention of Bone Loss in Postmenopausal Women With Low Bone Mass: A Randomized Controlled Trial. <i>Obstet Gynecol. </i>2009;114(5):999-1007.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/20168099/pubmed" id="20168099" target="_blank">20168099</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17136870">
<a name="17136870"></a>McDermott RS, Kloth DD, Wang H, Hudes GR, Langer CJ. Impact of zoledronic acid on renal function in patients with cancer: Clinical significance and development of a predictive model. <i>J Support Oncol</i>. 2006;4(10):524-529.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/17136870/pubmed" id="17136870" target="_blank">17136870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15244000">
<a name="15244000"></a>McMahon RE, Bouquot JE, Glueck CJ, et al. Osteonecrosis: A Multifactorial Etiology. <i>J Oral Maxillofac Surg.</i> 2004;62(7):904-905.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/15244000/pubmed" id="15244000" target="_blank">15244000</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29253322">
<a name="29253322"></a>Mhaskar R, Kumar A, Miladinovic B, Djulbegovic B. Bisphosphonates in multiple myeloma: an updated network meta-analysis. <i>Cochrane Database Syst Rev</i>. 2017;12(12):CD003188. doi:10.1002/14651858.CD003188.pub4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/29253322/pubmed" id="29253322" target="_blank">29253322</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17369566">
<a name="17369566"></a>Michaelson MD, Kaufman DS, Lee H, et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. <i>J Clin Oncol</i>. 2007;25(9):1038-1042. doi:10.1200/JCO.2006.07.3361<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/17369566/pubmed" id="17369566" target="_blank">17369566</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23907861">
<a name="23907861"></a>Miller PD, Jamal SA, Evenepoel P, Eastell R, Boonen S. Renal safety in patients treated with bisphosphonates for osteoporosis: a review. <i>J Bone Miner Res</i>. 2013;28(10):2049-2059. doi:10.1002/jbmr.2058<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/23907861/pubmed" id="23907861" target="_blank">23907861</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26037642">
<a name="26037642"></a>Minisola S, Pepe J, Piemonte S, Cipriani C. The diagnosis and management of hypercalcaemia. <i>BMJ</i>. 2015;350:h2723. doi:10.1136/bmj.h2723<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/26037642/pubmed" id="26037642" target="_blank">26037642</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22498739">
<a name="22498739"></a>Morgan GJ, Davies FE, Gregory WM, et al. Effects of Induction and Maintenance Plus Long-Term Bisphosphonates on Bone Disease in Patients With Multiple Myeloma: The Medical Research Council Myeloma IX Trial. <i>Blood.</i> 2012;119(23):5374-5383.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/22498739/pubmed" id="22498739" target="_blank">22498739</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17574945">
<a name="17574945"></a>Munns CF, Rajab MH, Hong J, et al. Acute phase response and mineral status following low dose intravenous zoledronic acid in children. <i>Bone</i>. 2007;41(3):366-370.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/17574945/pubmed" id="17574945" target="_blank">17574945</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-MSTS.1">
<a name="MSTS.1"></a>Musculoskeletal Tumor Society (MSTS), American Society for Radiation Oncology (ASTRO), and American Society of Clinical Oncology (ASCO). The treatment of metastatic carcinoma and myeloma of the femur: clinical practice guideline. http://msts.org/view/download.php/education/mbd-cpg-amended. Published 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32535678">
<a name="32535678"></a>Ng TL, Tu MM, Ibrahim MFK, et al. Long-term impact of bone-modifying agents for the treatment of bone metastases: a systematic review. <i>Support Care Cancer</i>. 2021;29(2):925-943. doi:10.1007/s00520-020-05556-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/32535678/pubmed" id="32535678" target="_blank">32535678</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30393090">
<a name="30393090"></a>Nicolatou-Galitis O, Schiødt M, Mendes RA, Ripamonti C, et al. Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment. <i>Oral Surg Oral Med Oral Pathol Oral Radiol</i>. 2019;127(2):117-135. doi:10.1016/j.oooo.2018.09.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/30393090/pubmed" id="30393090" target="_blank">30393090</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20061894">
<a name="20061894"></a>North American Menopause Society. Management of Osteoporosis in Postmenopausal Women: 2010 Position Statement of The North American Menopause Society. <i>Menopause.</i> 2010;17(1):25-54.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/20061894/pubmed" id="20061894" target="_blank">20061894</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34448749">
<a name="34448749"></a>North American Menopause Society. Management of osteoporosis in postmenopausal women: the 2021 position statement of the North American Menopause Society. <i>Menopause</i>. 2021;28(9):973-997. doi:10.1097/GME.0000000000001831<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/34448749/pubmed" id="34448749" target="_blank">34448749</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29082518">
<a name="29082518"></a>O'Carrigan B, Wong MH, Willson ML, Stockler MR, Pavlakis N, Goodwin A. Bisphosphonates and other bone agents for breast cancer. <i>Cochrane Database Syst Rev</i>. 2017;10:CD003474. doi:10.1002/14651858.CD003474.pub4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/29082518/pubmed" id="29082518" target="_blank">29082518</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18045781">
<a name="18045781"></a>Olson K, Van Poznak C. Significance and impact of bisphosphonate-induced acute phase responses. <i>J Oncol Pharm Pract</i>. 2007;13(4):223-229. doi:10.1177/1078155207080806<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/18045781/pubmed" id="18045781" target="_blank">18045781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25940768">
<a name="25940768"></a>Ott SM. Pharmacology of bisphosphonates in patients with chronic kidney disease. <i>Semin Dial</i>. 2015;28(4):363-369. doi:10.1111/sdi.12388<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/25940768/pubmed" id="25940768" target="_blank">25940768</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19570737">
<a name="19570737"></a>Papapetrou PD. Bisphosphonate-associated adverse events. <i>Hormones (Athens)</i>. 2009;8(2):96-110. doi:10.14310/horm.2002.1226<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/19570737/pubmed" id="19570737" target="_blank">19570737</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21343577">
<a name="21343577"></a>Park-Wyllie LY, Mamdani MM, Juurlink DN, et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. <i>JAMA</i>. 2011;305(8):783-789. doi:10.1001/jama.2011.190<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/21343577/pubmed" id="21343577" target="_blank">21343577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20091928">
<a name="20091928"></a>Pazianas M, Compston J, Huang CL. Atrial fibrillation and bisphosphonate therapy. <i>J Bone Miner Res</i>. 2010;25(1):2-10. doi:10.1359/jbmr.091201<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/20091928/pubmed" id="20091928" target="_blank">20091928</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32453819">
<a name="32453819"></a>Pepe J, Body JJ, Hadji P, et al. Osteoporosis in premenopausal women: a clinical narrative review by the ECTS and the IOF. <i>J Clin Endocrinol Metab</i>. Published online May 26, 2020. doi:10.1210/clinem/dgaa306<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/32453819/pubmed" id="32453819" target="_blank">32453819</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18685574">
<a name="18685574"></a>Perazella MA, Markowitz GS. Bisphosphonate nephrotoxicity.<i> Kidney Int</i>. 2008;74(11):1385-1393. doi:10.1038/ki.2008.356<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/18685574/pubmed" id="18685574" target="_blank">18685574</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22885424">
<a name="22885424"></a>Pereira RM, Carvalho JF, Paula AP, et al. Guidelines for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. <i>Rev Bras Reumatol.</i> 2012;52(4):580-593.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/22885424/pubmed" id="22885424" target="_blank">22885424</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28299378">
<a name="28299378"></a>Popp AW, Senn R, Curkovic I, et al. Factors associated with acute-phase response of bisphosphonate-naïve or pretreated women with osteoporosis receiving an intravenous first dose of zoledronate or ibandronate. <i>Osteoporos Int</i>. 2017;28(6):1995-2002. doi:10.1007/s00198-017-3992-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/28299378/pubmed" id="28299378" target="_blank">28299378</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18672105">
<a name="18672105"></a>Ralston SH. Pathogenesis of Paget's Disease of Bone. <i>Bone.</i> 2008;43(5):819-825.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/18672105/pubmed" id="18672105" target="_blank">18672105</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30803025">
<a name="30803025"></a>Ralston SH, Corral-Gudino L, Cooper C, et al. Diagnosis and management of Paget's disease of bone in adults: a clinical guideline. <i>J Bone Miner Res</i>. 2019;34(4):579-604. doi:10.1002/jbmr.3657<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/30803025/pubmed" id="30803025" target="_blank">30803025</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Reclast.1">
<a name="Reclast.1"></a>Reclast (zoledronic acid) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; April 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19362675">
<a name="19362675"></a>Reid DM, Devogelaer JP, Saag K, et al. Zoledronic Acid and Risedronate in the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis (HORIZON): A Multicentre, Double-Blind, Double-Dummy, Randomised Controlled Trial. <i>Lancet.</i> 2009;373(9671):1253-1263.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/19362675/pubmed" id="19362675" target="_blank">19362675</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20554708">
<a name="20554708"></a>Reid IR, Gamble GD, Mesenbrink P, Lakatos P, Black DM. Characterization of and risk factors for the acute-phase response after zoledronic acid. <i>J Clin Endocrinol Metab</i>. 2010;95(9):4380-4387. doi:10.1210/jc.2010-0597<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/20554708/pubmed" id="20554708" target="_blank">20554708</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30575489">
<a name="30575489"></a>Reid IR, Horne AM, Mihov B, et al. Fracture prevention with zoledronate in older women with osteopenia. <i>N Engl J Med</i>. 2018;379(25):2407-2416. doi:10.1056/NEJMoa1808082<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/30575489/pubmed" id="30575489" target="_blank">30575489</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16135834">
<a name="16135834"></a>Reid IR, Miller P, Lyles K, et al. Comparison of a Single Infusion of Zoledronic Acid With Risedronate for Paget's Disease. <i>N Engl J Med.</i> 2005;353(9):898-908.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/16135834/pubmed" id="16135834" target="_blank">16135834</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22649132">
<a name="22649132"></a>Renouf D, Velazquez-Martin JP, Simpson R, et al. Ocular Toxicity of Targeted Therapies. <i>J Clinl Oncol.</i> 2012;30(26):3277-3286.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/22649132/pubmed" id="22649132" target="_blank">22649132</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29623207">
<a name="29623207"></a>Richa CG, Saad KJ, Chaaban AK, El Rawas MS. A rare case of hypercalcemia-induced pancreatitis in a first trimester pregnant woman. <i>Endocrinol Diabetes Metab Case Rep</i>. 2018;2018. pii: 17-0175. doi:10.1530/EDM-17-0175<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/29623207/pubmed" id="29623207" target="_blank">29623207</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12686715">
<a name="12686715"></a>Rosen CJ, Brown S. Severe hypocalcemia after intravenous bisphosphonate therapy in occult vitamin D deficiency. <i>N Engl J Med</i>. 2003;348(15):1503-1504. doi:10.1056/NEJM200304103481521<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/12686715/pubmed" id="12686715" target="_blank">12686715</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rosen.1">
<a name="Rosen.1"></a>Rosen HN, Drezner MK. Overview of the management of osteoporosis in postmenopausal women. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 20, 2022a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rosen.2">
<a name="Rosen.2"></a>Rosen HN, Saag KG. Prevention and treatment of glucocorticoid-induced osteoporosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 20, 2022b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14534891">
<a name="14534891"></a>Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. <i>Cancer</i>. 2003;98(8):1735-1744. doi:10.1002/cncr.11701<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/14534891/pubmed" id="14534891" target="_blank">14534891</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11693896">
<a name="11693896"></a>Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. <i>Cancer J</i>. 2001;7(5):377-387.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/11693896/pubmed" id="11693896" target="_blank">11693896</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ruggiero.2006">
<a name="Ruggiero.2006"></a>Ruggiero S, Gralow J, Marx RE, et al. Practical Guidelines for the Prevention, Diagnosis, and Treatment of Osteonecrosis of the Jaw in Patients With Cancer. <i>J Clin Oncol.</i> 2006;2(1):7-14.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25234529">
<a name="25234529"></a>Ruggiero SL, Dodson TB, Fantasia J, et al; American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. <i>J Oral Maxillofac Surg</i>. 2014;72(10):1938-1956. doi:10.1016/j.joms.2014.04.031<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/25234529/pubmed" id="25234529" target="_blank">25234529</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19205753">
<a name="19205753"></a>Sayin M and Yazici G. Hyperparathyroidism Secondary to Zoledronic Acid Infusion: Case Report. <i>Support Care Cancer.</i> 2009;17(5):469-470.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/19205753/pubmed" id="19205753" target="_blank">19205753</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31990618">
<a name="31990618"></a>Saylor PJ, Rumble RB, Tagawa S, et al. Bone health and bone-targeted therapies for prostate cancer: ASCO endorsement of a Cancer Care Ontario guideline. <i>J Clin Oncol</i>. 2020;38(15):1736-1743. doi:10.1200/JCO.19.03148<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/31990618/pubmed" id="31990618" target="_blank">31990618</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14675064">
<a name="14675064"></a>Schwarz C, Mitterbauer C, Heinze G, Woloszczuk W, Haas M, Oberbauer R. Nonsustained effect of short-term bisphosphonate therapy on bone turnover three years after renal transplantation. <i>Kidney Int</i>. 2004;65(1):304-309.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/14675064/pubmed" id="14675064" target="_blank">14675064</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7572320">
<a name="7572320"></a>Schweitzer DH, Oostendorp-van de Ruit M, Van der Pluijm G, Löwik CW, Papapoulos SE. Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate. <i>J Bone Miner Res</i>. 1995;10(6):956-962. doi:10.1002/jbmr.5650100617<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/7572320/pubmed" id="7572320" target="_blank">7572320</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20924014">
<a name="20924014"></a>Sellmeyer DE. Atypical Fractures as a Potential Complication of Long-term Bisphosphonate Therapy. <i>JAMA.</i> 2010;304(13):1480-1484.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/20924014/pubmed" id="20924014" target="_blank">20924014</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Shane.2020">
<a name="Shane.2020"></a>Shane E, Berenson JR. Treatment of hypercalcemia. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 17, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23712442">
<a name="23712442"></a>Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. <i>J Bone Miner Res</i>. 2014;29(1):1-23. doi:10.1002/jbmr.1998<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/23712442/pubmed" id="23712442" target="_blank">23712442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20842676">
<a name="20842676"></a>Shane E, Burr D, Ebeling PR, et al. Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Report of a Task Force of the American Society for Bone and Mineral Research. <i>J Bone Miner Res.</i> 2010;25(11):2267-2294.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/20842676/pubmed" id="20842676" target="_blank">20842676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31532726">
<a name="31532726"></a>Shapiro CL, Van Poznak C, Lacchetti C, et al. Management of osteoporosis in survivors of adult cancers with nonmetastatic disease: ASCO clinical practice guideline. <i>J Clin Oncol</i>. 2019;37(31):2916-2946. doi:10.1200/JCO.19.01696<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/31532726/pubmed" id="31532726" target="_blank">31532726</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23184667">
<a name="23184667"></a>Sieber P, Lardelli P, Kraenzlin CA, Kraenzlin ME, Meier C. Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice. <i>Clin Drug Investig</i>. 2013;33(2):117-122. doi:10.1007/s40261-012-0041-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/23184667/pubmed" id="23184667" target="_blank">23184667</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25406796">
<a name="25406796"></a>Singer FR, Bone HG 3rd, Hosking DJ, et al; Endocrine Society. Paget's disease of bone: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2014;99(12):4408-4422. doi:10.1210/jc.2014-2910<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/25406796/pubmed" id="25406796" target="_blank">25406796</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24577348">
<a name="24577348"></a>Siris ES, Adler R, Bilezikian J, et al. The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group. <i>Osteoporos Int</i>. 2014;25(5):1439-1443. doi:10.1007/s00198-014-2655-z.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/24577348/pubmed" id="24577348" target="_blank">24577348</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12771706">
<a name="12771706"></a>Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. <i>J Urol.</i> 2003;169(6):2008-2012.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/12771706/pubmed" id="12771706" target="_blank">12771706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30171300">
<a name="30171300"></a>Sokal A, Elefant E, Leturcq T, Beghin D, Mariette X, Seror R. Pregnancy and newborn outcomes after exposure to bisphosphonates: a case-control study. <i>Osteoporos Int</i>. 2019;30(1):221-229.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/30171300/pubmed" id="30171300" target="_blank">30171300</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32303862">
<a name="32303862"></a>Spångeus A, Johansson S, Woisetschläger M. Adherence to and persistence with zoledronic acid treatment for osteoporosis-reasons for early discontinuation. <i>Arch Osteoporos</i>. 2020;15(1):58. doi:10.1007/s11657-020-00733-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/32303862/pubmed" id="32303862" target="_blank">32303862</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22281884">
<a name="22281884"></a>Stathopoulos IP, Liakou CG, Katsalira A, et al. The Use of Bisphosphonates in Women Prior to or During Pregnancy and Lactation. <i>Hormones (Athens).</i> 2011;10(4):280-291.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/22281884/pubmed" id="22281884" target="_blank">22281884</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28176386">
<a name="28176386"></a>Tan A, Goodman K, Walker A, et al; PRISM-EZ Trial Group. Long-term randomized trial of intensive versus symptomatic management in Paget's disease of bone: the PRISM-EZ study. <i>J Bone Miner Res</i>. 2017;32(6):1165-1173. doi:10.1002/jbmr.3066<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/28176386/pubmed" id="28176386" target="_blank">28176386</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14586868">
<a name="14586868"></a>Tarassoff P and Csermak K. Avascular Necrosis of the Jaws: Risk Factors in Metastatic Cancer Patients. <i>J Oral Maxillofac Surg.</i> 2003;61(10):1238-1239.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/14586868/pubmed" id="14586868" target="_blank">14586868</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16547070">
<a name="16547070"></a>Tanvetyanon T, Stiff PJ. Management of the adverse effects associated with intravenous bisphosphonates. <i>Ann Oncol</i>. 2006;17(6):897-907. doi:10.1093/annonc/mdj105<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/16547070/pubmed" id="16547070" target="_blank">16547070</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9351880">
<a name="9351880"></a>Thiébaud D, Sauty A, Burckhardt P, et al. An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates. <i>Calcif Tissue Int</i>. 1997;61(5):386-392. doi:10.1007/s002239900353<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/9351880/pubmed" id="9351880" target="_blank">9351880</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27492436">
<a name="27492436"></a>Trejo P, Rauch F. Osteogenesis imperfecta in children and adolescents-new developments in diagnosis and treatment. <i>Osteoporos Int</i>. 2016;27(12):3427-3437.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/27492436/pubmed" id="27492436" target="_blank">27492436</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29403337">
<a name="29403337"></a>Umunakwe OC, Herren D, Kim SJ, Kohanim S. Diffuse ocular and orbital inflammation after zoledronate infusion-case report and review of the literature. <i>Digit J Ophthalmol</i>. 2017;23(4):18-21. doi:10.5693/djo.02.2017.08.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/29403337/pubmed" id="29403337" target="_blank">29403337</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-VanPoznak.1">
<a name="VanPoznak.1"></a>Van Poznak C. Use of osteoclast inhibitors in early breast cancer. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 26, 2022a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-VanPoznak.2">
<a name="VanPoznak.2"></a>Van Poznak C, Clemons M. Osteoclast inhibitors for patients with bone metastases from breast, prostate, and other solid tumors. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 20, 2022b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29035643">
<a name="29035643"></a>Van Poznak C, Somerfield MR, Barlow WE, et al. Role of bone-modifying agents in metastatic breast cancer: an American Society of Clinical Oncology-Cancer Care Ontario focused guideline update. <i>J Clin Oncol</i>. 2017;35(35):3978-3986. doi:10.1200/JCO.2017.75.4614<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/29035643/pubmed" id="29035643" target="_blank">29035643</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22675062">
<a name="22675062"></a>Watts NB, Adler RA, Bilezikian JP, et al; Endocrine Society. Osteoporosis in men: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2012;97(6):1802-1822. doi:10.1210/jc.2011-3045<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/22675062/pubmed" id="22675062" target="_blank">22675062</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20173017">
<a name="20173017"></a>Watts NB, Diab DL. Long-term use of bisphosphonates in osteoporosis. <i>J Clin Endocrinol Metab</i>. 2010;95(4):1555-1565. doi:10.1210/jc.2009-1947<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/20173017/pubmed" id="20173017" target="_blank">20173017</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16899779">
<a name="16899779"></a>Whyte MP. Clinical Practice. Paget's Disease of Bone. <i>N Engl J Med.</i> 2006;355(6):593-600.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/16899779/pubmed" id="16899779" target="_blank">16899779</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20940190">
<a name="20940190"></a>Wilkinson GS, Baillargeon J, Kuo YF, Freeman JL, Goodwin JS. Atrial fibrillation and stroke associated with intravenous bisphosphonate therapy in older patients with cancer. <i>J Clin Oncol</i>. 2010;28(33):4898-905. doi:10.1200/JCO.2010.28.7524<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/20940190/pubmed" id="20940190" target="_blank">20940190</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21841837">
<a name="21841837"></a>Woo KT, Chan CM. KDIGO clinical practice guidelines for bisphosphonate treatment in chronic kidney disease. <i>Kidney Int</i>. 2011;80(5):553-554; author reply 554. doi:10.1038/ki.2011.202<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/21841837/pubmed" id="21841837" target="_blank">21841837</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30251313">
<a name="30251313"></a>Yamada S, Arase H, Tachibana S, et al. Immobilization-induced severe hypercalcaemia successfully treated with reduced dose of zoledronate in a maintenance haemodialysis patient. <i>Nephrology (Carlton)</i>. 2018;23(10):963-964. doi:10.1111/nep.13246<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/30251313/pubmed" id="30251313" target="_blank">30251313</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23690271">
<a name="23690271"></a>Yazici O, Aksoy S, Ucar O, Ozdemir N, Demir M, Sendur MA, Arik Z, Yaman S, Eren T, Uncu D, Zengin N. Arrhythmias during and after zoledronic acid infusion patients with bone metastasis. <i>Med Oncol</i>. 2013;30(3):609. doi:10.1007/s12032-013-0609-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/23690271/pubmed" id="23690271" target="_blank">23690271</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21532237">
<a name="21532237"></a>Yoshinami T, Yagi T, Sakai D, Sugimoto N, Imamura F. A case of acquired Fanconi syndrome induced by zoledronic acid. <i>Intern Med</i>. 2011;50(9):1075-1079. doi:10.2169/internalmedicine.50.4855<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/21532237/pubmed" id="21532237" target="_blank">21532237</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sagent.1">
<a name="Sagent.1"></a>Zoledronic acid injection [prescribing information]. Schaumberg, IL: Sagent Pharmaceuticals; October 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Caraco.1">
<a name="Caraco.1"></a>Zoledronic acid powder for injection [prescribing information]. Detroit, MI: Caraco; November 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hospira.1">
<a name="Hospira.1"></a>Zoledronic acid premixed solution for IV infusion [prescribing information]. Lake Forest, IL: Hospira; October 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Novartis.1">
<a name="Novartis.1"></a>Zometa (zoledronic acid) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; December 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.1">
<a name="Expert.1"></a>Based on expert opinion.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer labeling.</div>
</li></ol></div><div id="topicVersionRevision">Topic 9902 Version 479.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
